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Resumen 
Los linfocitos T citotóxicos CD8+ (CTL) exploran la superficie de las células del 
organismo en busca de anomalías, lo que permite su correcta eliminación. Para que esto 
sea posible, las células del organismo procesan proteínas tanto endógenas como 
derivadas de patógenos, generando péptidos que se cargan y presentan en moléculas del 
complejo principal de histocompatibilidad de clase I (MHC-I). La presentación de 
antígenos por la vía clásica involucra al transportador asociado a presentación antigénica 
(TAP). Este transportador permite a los antígenos peptídicos acceder al retículo 
endoplasmático, donde se asocian los complejos MHC-I. Sin embargo, se han descrito 
diferentes epítopos que se presentan de forma independiente de este transportador.  
Nos propusimos caracterizar la o las proteasas implicadas en la presentación 
independiente de TAP. Utilizando linfocitos T CD8+ purificados de bazos de ratones 
C57BL/6 infectados con el virus vaccinia y células dendríticas derivadas de médula ósea 
(BMDC), estudiamos la importancia del proteasoma en la presentación de antígenos 
independientes de TAP. Midiendo la activación mediante la técnica de tinción intracelular 
de citoquinas (ICS) de los linfocitos T CD8+ purificados estimamos que tras el tratamiento 
con el inhibidor del proteasoma lactacistina (LC) a BMDC de ratones C57BL/6 y TAP1-/-, la 
inhibición de la presentación de antígeno es fuerte y similar en ambos casos. Por tanto, al 
igual que en las BMDC silvestres, el proteasoma juega un papel principal en la 
presentación de antígenos en BMDC deficientes en TAP. 
Con el objetivo de caracterizar proteasas alternativas involucradas en el 
procesamiento de antígenos virales estudiamos, para una batería de ocho epítopos, la 
activación de CTL monoespecíficos tras estimularlos con BMDC infectadas y tratadas con  
inhibidores de diferentes proteasas. Sólo observamos un efecto sobre la presentación 
antigénica tras el tratamiento con el inhibidor de pro-protein convertasas dec-RVKR-cmk, 
que inhibió en gran medida la presentación de uno de los ocho epítopos. 
Una vez conocida la existencia de mecanismos alternativos de presentación en 
MHC-I, quisimos saber si estos tenían relevancia fisiológica en una infección por el virus 
vaccinia. Para ello, inoculamos tanto ratones silvestres como TAP1-/- con BMDC cargadas 
con péptidos sintéticos. Tras catorce días, infectamos los ratones con virus vaccinia y 
medimos la carga viral a diferentes días post-infección y en diferentes órganos. En bazo, 
observamos un efecto protector de los tres péptidos tanto en los ratones silvestres como 
en los ratones TAP1-/-. Estos resultados sugieren que distintos tipos celulares podrían 
tener activas distintas vías alternativas de procesamiento antigénico, siendo más 
relevantes en unos órganos que en otros. También, confirman la existencia de las vías 
independientes de TAP descritas previamente en el laboratorio para los epítopos 
estudiados. 
 
 
 
 
 
 
 
 
Abstract 
CD8+ cytotoxic T lymphocytes (CTL) screen the surface of the cells in the 
organism in seek of abnormalities, which allows their correct elimination. This is possible 
because the cells in the organism process proteins, either self-proteins or pathogen-
derived. This degradation generates peptides that are loaded and presented on class I 
major histocompatibility complexes molecules (MHC-I). The presentation of antigens 
through the classical pathway involves the transporter associated to antigen processing 
(TAP). This transporter allows peptidic antigens access the endoplasmic reticulum, where 
they are loaded onto MHC-I complexes. However, different epitopes that are presented in 
a TAP-independent manner have been described.  
We aimed to characterize the protease or proteases involved in the TAP-
independent antigen presentation. Using CD8+ T lymphocytes purified from spleens from 
VACV-infected C57BL/6 mice and dendritic cells derived from bone marrow (BMDC), we 
studied the importance of the proteasome in TAP-independent VACV antigen 
presentation. Measuring CD8+ T lymphocyte activation by intracellular cytokine staining 
(ICS), we estimated that, after treatment of C57BL/6 and TAP1-/- VACV-infected BMDC 
with the proteasome inhibitor lactacystin (LC), the inhibition of the antigen presentation is 
strong and similar in both cases. Therefore, just like in wild type BMDC, proteasomes play 
a key role in TAP-independent VACV antigen presentation in BMDC.  
With the aim of characterizing alternative proteases involved in the antigen 
processing we studied, for eight peptides, the activation of monospecific CTL after VACV-
infected BMDC stimulation. These BMDC were also treated with inhibitors of different 
proteases. We only observed an effect on antigen presentation after the treatment with the 
pro-protein convertases inhibitor dec-RVKR-cmk, which inhibited the presentation of one 
epitope. 
Once we acknowledged the existence of alternative MHC-I antigen presentation 
mechanisms, we wanted to know whether these had any physiological relevance on a 
VACV infection. For that, we inoculated C57BL/6 as well as TAP1 -/- mice with synthetic 
peptide-loaded BMDC. After fourteen days, we infected the mice with VACV and 
measured the viral load at different days post-infection and in different organs. In spleens 
we observed a protective effect by the three peptides included in the study in C57BL/6 as 
well as in TAP1-/- mice. These results suggest that different cell types may have different 
alternative antigen processing pathways activated, being more relevant in some organs 
than in others. Also, they confirm the existence of previously described VACV antigen 
processing TAP-independent routes. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
“Quien no sabe lo que busca no entiende lo que encuentra” 
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1. ABBREVIATIONS. 
aa amino acid 
ABC ATP-binding cassette 
ACE Angiotensin convertase enzyme 
APC Antigen presenting cell 
AraC Cytosine arabinoside 
BFA Brefeldin A 
BH Bleomycin hydrolase 
BHV Bovine herpes virus 
BMDC Bone marrow-derived dendritic cells 
BSA Bovine serum albumin 
CD Cluster of differentiation 
CMV Murine cytomegalovirus 
COP Copenhagen 
CPRG Chlorophenol red-β-D-galactopyranoside 
CPXV Cowpox virus 
CTL CD8+ Cytotoxic T Lymphocytes 
Cyt Cytoplasmic 
d.p.i. Days post-infection 
DC Dendritic cell 
dec-RVKR-cmk Decanoyl-Arg-Val-Lys-Arg-chloromethylketone 
DNA Deoxyribonucleic acid 
DPP-III Dipeptidyl-peptidase III 
DRiPs Defective ribosomal products 
E:T Effector:Target 
EBV Epstein Barr Virus 
EHV Equine herpes virus 
Epo Epoxomicin 
ER Endoplasmic reticulum 
ERAD Endoplasmic-reticulum-associated degradation 
ERAP Endoplasmic reticulum aminopeptidase 
EV Extracellular virion 
FBS Fetal bovine serum 
GFP Green fluorescent protein 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
HCMV Human cytomegalovirus 
HIV Human immunodeficiency virus 
HSV Herpes simplex virus 
ICS Intracellular cytokine staining 
IDE Insulin-degrading enzyme 
IFN Interferon 
IL Interleukin 
IRAP Insulin-responsive aminopeptidase 
IV Immature virion 
LacZ Bacterial beta-galactosidase gene 
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LAP Leucine aminopeptidase 
LC Lactacystin 
LCE LC-enhanced 
LCR LC-resistant 
LCS LC-sensitive 
LPS Lipopolysaccharide 
LV Lentivirus 
m.o.i. Multiplicity of infection 
MALDI-TOF Matrix-assisted laser desorption/ionization time-of-flight 
MHC Major histocompatibility complex 
MHC-I Major histocompatibility complex class I 
mRNA messenger ribonucleic acid 
MV Mature virion 
NBD Nucleotide-binding domain 
NK Natural killer 
NLVS Tri-leucine vinyl sulfone 
NP Nucleoprotein 
OHM Optimal matching hydrophobicities 
ORF Open reading frame 
OVA Ovalbumin 
PBS Phosphate-buffered saline 
PC7 Proprotein convertase 7 
PEC Peritoneal exudate cells 
PFA Paraformaldehyde 
PFU Plaque-forming unit 
PLC Peptide loading complex 
PR Post-replicative 
PRV Pseudorabies virus 
PSA Puromycin-sensitive aminopeptidase 
r.p.m. Revolutions per minute 
R.T. Room temperature 
RNA Ribonucleic acid 
RQ Relative quantification 
RT-qPCR Reverse transciption quantitative polymerase chain reaction 
rVACV Recombinant vaccinia virus 
rVACV-OVA Recombinant VACV expressing full-length OVA 
rVV-GFP Recombinant VACV expressing GFP 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM Standard error of the mean 
SNARE 
Soluble N-ethylmaleimide-sensitive fusion protein-attachment protein 
receptor 
SP Signal peptidase 
SPP Signal peptide peptidase 
SV40 Simian virus 40 
7 
 
TAP Transporter associated to antigen processing 
TAP-dep TAP-dependent 
TAP-ind TAP-independent 
TAPL Transporter associated to antigen processing-like 
TCR T Cell Receptor 
TEIPP T-cell epitopes associated with impaired peptide processing 
TM Transmembrane 
TMD Transmembrane domain 
TOP Thimet oligopeptidase 
TPPII Tripeptidyl-peptidase II 
VACV Vaccinia virus 
WR Western reserve 
WT Wild type 
WV Wrapped virion 
z-VAD-fmk N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone 
β2m β2 microglobulin 
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2. INTRODUCTION. 
2.1. MHC-I antigen processing. 
CD8+ Cytotoxic T Lymphocytes (CTL) screen the surface of all cells in the organism in 
order to detect tumors or infections caused by a pathogen and thus, eliminate the tumoral or 
infected cell. Their T Cell Receptor (TCR) recognizes peptides displayed at the plasma 
membrane by major histocompatibility complex (MHC) class I molecules. These peptides are 
derived from the proteolytic processing of endogenous proteins either from the host or from 
the pathogen. In professional antigen presenting cells (APC) these peptides can also derive 
from the processing of exogenous proteins in a process named cross-presentation. These 
peptides have an average length of 9 aminoacids (aa) and they are frequently derived from 
larger precursors that require a proteolytic trimming previous to MHC class I (MHC-I) loading. 
The specific recognition of MHC/peptide complex by the TCR triggers CTL activation and 
proliferation, promoting the tumoral or infected cell elimination by their cytotoxic activity or 
cytokine release. 
In the classical antigen processing pathway, antigenic peptides are originated by 
cytosolic degradation of endogenous proteins or defective ribosomal products (DRiP) via the 
proteasome. The products generated by the proteasome are mainly peptides shorter than 8 
aa, although it also generates peptides of 8 aa or longer that may contain epitopes or their 
precursors. These precursors might have in their amino termini extensions of several aa that 
can be trimmed by cytosolic aminopeptidases. Thus, peptides generated in the cytosol are 
transported to the endoplasmic reticulum (ER) through the transporter associated with 
antigen processing (TAP). Further trimming of these peptides can be performed by either ER 
aminopeptidases (ERAP) or the carboxy-dipeptidase angiotensin convertase enzyme (ACE). 
At this point, peptides are loaded onto a complex formed by nascent heavy MHC-I chains 
and β2 microglobulin (β2m) with the aid of the chaperones tapasin, calreticulin and ERp57. 
The complex formed by TAP, tapasin, calreticulin, ERp57 and MHC-I is known as the peptide 
loading complex (PLC). The stable MHC/peptide complex is further transported through the 
constitutive secretory pathway to the plasma membrane, where CD8+ cytotoxic T 
lymphocytes efficiently recognize and eliminate the infected cell. 
2.1.1. Proteases involved in MHC-I antigen processing. 
2.1.1.1. Proteasomes. 
 The proteasome is a multiproteic complex that functions as the main degradative 
endoprotease in the cell. It is highly conserved and is found in cytosol and nucleus. The 26S 
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proteasome is a multiproteic complex with proteolytic activity that belongs to the ubiquitin-
proteasome system. The enzymatic cascade E1, E2 and E3 transfers multiple ubiquitins to ε-
amino groups in lysine residues localized in protein targets to be degraded by the 
proteasome. The 26S proteasome is formed by 33 canonical subunits arranged into two 
complexes: a 20S catalytic core and two 19S regulatory subunits flanking the core [19S-20S-
19S] (Wehmer and Sakata, 2016). These regulatory subunits are responsible for the binding 
and unfolding of polyubiquitylated substrates. The 20S core is constituted by 28 different 
subunits and are organized forming 4 rings that stack together to shape a barrel-like 
conformation (Groll et al., 1997). Both external rings are constituted by 7 α subunits (α1-α7) 
that avoid the recruitment of non-selective substrates. The interaction between 20S core, the 
activating complex PA28 and the regulative 19S subunit produces a change in the orientation 
of external α subunits that allow the entry of substrates and the release of products. Each of 
the 2 inner rings is constituted by 7 catalytic β subunits (β1-β7) that form an inner pocket 
where substrate degradation can take place. The catalytic subunits in the active site have 
different proteolytic activities; caspase-like (β1), trypsin-like (β2) and chymotrypsin-like (β5). 
These activities vary among species, cell types and disease state (Priestman et al., 
2014).Proteasome cleavage specificity is low since any aa can serve as a cleavage site. 
There are several reasons why the proteasome has been implicated in the generation 
of MHC-I epitopes:  
First, specific inhibitors of the proteasomal activity suppress almost completely the 
presentation of some MHC-I epitopes. Proteasomes also strongly affect, although to different 
extents for different allotypes, MHC-I molecule expression at the cell surface. Also, the lack 
of carboxypeptidase activity in the cytosol (Reits et al., 2004; Reits et al., 2003) and in the 
ER of rat cells (Powis et al., 1996) showed that the C-termini of MHC-I ligands must be 
generated by an endoprotease. In fact, it has been demonstrated that the proteasome 
generates the exact carboxy termini of some epitopes presented to CTL (Shastri et al., 
2005). However, it has been recently described an important role for the carboxy-dipeptidase 
angiotensin convertase enzyme (ACE) in the generation of the carboxy termini of some 
epitopes in the secretory pathway (Shen et al., 2011). This finding has questioned the 
proteasome as the sole MHC-I ligand carboxy terminus generating enzyme. 
Secondly, the proteasome generates peptides from 3 to 22 residues. Fifteen percent 
of them have the optimal length to bind MHC-I molecules (8-10 aa long). On the other hand, 
20% of the peptides generated by the proteasome are longer than 8-10 aa, being potential 
precursors of the final peptide (Kisselev et al., 1999). 
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Finally, interferon (IFN) γ induces the incorporation of new β-catalytic subunits to 
nascent proteasomes, LMP2, MELC-1 and LMP7, and they replace the constitutive catalytic 
subunits β1, β2 and β5, respectively. The resulting proteasome is denominated 
immunoproteasome, and it is constitutively localized in lymphoid tissues such as thymus, 
spleen or lymph nodes and in other cell types under IFNγ stimulation. Immunoproteasomes 
do not have the same cleavage specificity as standard proteasomes, which could change the 
repertoire of peptides generating a different peptide pool or generating the same peptides 
with different efficiencies (Kloetzel and Ossendorp, 2004; Sijts and Kloetzel, 2011; Sijts and 
Kloetzel, 2011). 
 The main role of the proteasome is the degradation of unfolded proteins for aa 
recycling or the turnover of proteins. Proteins that get into the ER and fail to pass the quality 
control requirements must be retrotranslocated to the cytosol for their degradation in the 
endoplasmic-reticulum-associated degradation (ERAD) pathway, involving the Sec61 
channel also known as translocon (Wiertz et al., 1996). DRiP represent the main, but not the 
sole, source of peptides that are presented by MHC-I. The DRiP hypothesis explains how 
fast viral peptides are presented on the infected cell surface, since it links the defective 
protein translation to the antigen processing machinery (Del Val and López, 2002; Princiotta 
et al., 2003; Yewdell and Nicchitta, 2006; Dolan et al., 2011). 
Under proinflammatory conditions, a big amount of unfolded and oxidized proteins is 
generated, exceeding the degradative activity of the ubiquitin-proteasome system. As a 
result, these proteins are accumulated in the cell, unbalancing the protein turnover. The main 
role of the immunoproteasome in these conditions is to maintain the protein homeostasis. 
Also, the combination of both activities, proteasomal and immunoproteasomal, leads to an 
enrichment of the generation of peptides available for antigen presentation by MHC-I. 
Even though the inhibition of the proteasome has indeed a deep effect in MHC-I 
ligands generation (Kessler et al., 2003), for certain epitopes proteasomal cleavage can be 
necessary but not sufficient, since further trimming of proteasome-generated precursors by 
other proteases might be needed (Kessler et al., 2011; Shen et al., 2011). Thus, the 
sensitivity to proteasome inhibitors in the presentation of an epitope does not exclude the 
participation of other proteases in its generation. 
2.1.1.2. Cytosolic aminopeptidases and endopeptidases. 
Antigen processing involves other proteases apart from the proteasome. They are 
individually described and summarized in Table 1.  
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The cytosol is a highly degradative environment, and it is the location of many 
peptidases that rapidly degrade peptides. Particularly, the analysis of living cells incubated 
with labeled peptides, shows that these peptides are degraded within seconds by 
aminopeptidases, since N-terminally-protected peptides are stable(Reits et al., 2004; Reits et 
al., 2003). Cytosolic aminopeptidases cooperate to degrade peptides into aa, a key process 
for cell survival. They can also trim the amino terminus of extended precursors, resulting 
either in the generation of the correct MHC-I ligand terminus, or in its destruction. Although 
most proteasomal products require further proteolytic trimming in order to generate the 
correct amino terminus, it has been described an unusual natural ligand that is 15 aa long 
with 6 extended aa in its amino terminus that are not trimmed and is correctly presented to 
CTL (Samino et al., 2006). 
 Several cytosolic aminopeptidases have been described, such as the leucine 
aminopeptidase (LAP), bleomycin hydrolase (BH) or the puromycin-sensitive aminopeptidase 
(PSA). LAP is a metallopeptidase with preference for hydrophobic aa in the amino terminus 
(Turzynski and Mentlein, 1990). It is induced by IFNγ and promotes the in vitro generation of 
an epitope from an N-terminally-extended peptide (Beninga et al., 1998). PSA and BH can 
trim N-terminal extensions from long peptides to generate in vitro the correct epitope (Lévy et 
al., 2002; Stoltze et al., 2000). However, there are epitopes that do not require these 
aminopeptidases at all. Mice deficient in each of these peptidases show a normal surface 
MHC-I expression and they exhibit the same CD8+ T lymphocyte response against viral 
epitopes as wild-type mice (Towne et al., 2005; Towne et al., 2007). Only in splenic DCs 
deficient in PSA, an increase in MHC-I expression has been observed, but it does not 
correlate with a better antiviral CD8+ T lymphocytic response (Towne et al., 2008). 
Subcellular 
localization 
Non-proteasomal proteolytic enzymes 
Collaborative Alternative  
 
 
 
Cytosol   
 
  
  
  
Leucine aminopeptidase (LAP) Tripeptidyl-peptidase II (TPPII) 
Bleomycin hydrolase (BH) Caspases 3, 5, 8 and 10 
Puromycin-sensitive aminopeptidase 
(PSA) 
Insuling-degrading enzyme (IDE) 
Thimet oligopeptidase (TOP)  
Nardilysin  
Dipeptidyl-peptidase III (DPP-III)  
 
 
ER and vesicular 
pathways 
  
  
  
ERAP1 and ERAP2 Signal peptidase (SP) 
 
Signal peptide peptidase (SPP) 
 Furin 
Proprotein convertase 7 (PC7)* Cathepsins 
Angiotensin convertase enzyme (ACE)  
Insuyline responsive enzyme (IRAP)  
 Transport mechanisms 
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ER 
TAP 
Signal sequence via Sec61 
Table 1. Non-proteasomal proteolytic enzymes and transport mechanisms involved in 
MHC-I antigen processing. 
Different proteolytic activities and transport mechanisms involved in collaborative with proteasome or 
completely proteasome-independent (alternative) pathways, as well as their subcellular localization, 
are summarized and compared. *Collaboration with proteasome is unknown. 
Tripeptidyl-peptidase II (TPPII) is a cytosolic aminopeptidase that belongs to the 
subtilisin family and participates in many cellular processes, such as cell division, apoptosis 
or diseases like obesity and cancer. TPPII removes tripeptides from substrates in their amino 
termini unless it finds a proline (Tomkinson, 1999). It has also trypsin-like endoprotease 
activity. Peptides longer than 15 aa are processed mainly by TPPII rather than other 
aminopeptidases, so TPPII could play an important role as a cytosolic peptidase of large 
proteasomal products (Reits et al., 2004; York et al., 2006). TPPII was once proposed as a 
substitute of the proteasome when the latter is inhibited, since cells adapted to grow in the 
presence of the proteasome inhibitor tri-leucine vinyl sulfone (NLVS) overexpress the 
protease TPPII (Glas et al., 1998; Geier et al., 1999). However, as it has been reviewed (van 
Endert, 2008), antigen presentation by MHC-I was strongly compromised in NLVS-adapted 
cells (Kessler et al., 2003). Therefore, TPPII is currently understood as a cooperator instead 
of a substitute of the proteasomal activity (van Endert, 2008). 
  Several studies describe many endoproteases that either complement the action of 
the proteasome or act independently, generating epitopes presented by MHC-I. 
 Caspases are endoproteases that belong to a cytosolic cysteine-proteases family and 
are involved in the inflammatory response and apoptotic processes. It is known that 
caspases 5 and 10 participate in a proteasome-independent manner in the production of an 
epitope of murine cytomegalovirus (CMV) in apoptotic cells infected by a recombinant 
vaccinia virus (rVACV). Only the inhibition of both proteases together with the proteasome 
succeeds in completely eliminating epitope presentation (López et al., 2010). 
The insulin-degrading enzyme (IDE) is an ubiquous metalloprotease that cleaves 
insulin chain and peptides smaller than 12 kDa. This enzyme recognizes the substrate 
conformation and cleaves preferentially substrates with a beta sheet primary structure. There 
is an epitope of the tumoral protein MAGE-3 presented by HLA-A1 whose processing occurs 
in a proteasome-independent manner and is cleaved in the cytosol by IDE (Parmentier et al., 
2010). 
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 The thimet oligopeptidase (TOP) is a ubiquous cytosolic endoprotease whose main 
action results in epitope degradation (Saric et al., 2001), though it can also generate 
precursor peptides (Saric et al., 2004), such as the case of the tumoral protein MART-1 
(Kessler et al., 2011). TOP can also trim peptides generating the carboxy terminus of a 
MHC-I ligand by removing 2 or 3 residues from it. That is the case of an epitope from the 
tumoral protein PRAME, whose carboxy terminus generation is resistant to proteasome 
inhibitors (Kessler et al., 2011). 
 Nardilyisine is a cytosolic endopeptidase that recognizes dibasic motifs. It participates 
in the generation of precursor peptides of the tumoral protein PRAME and in the correct 
amino terminus of the epitope EBNA3C (Kessler et al., 2011).  
Even though testing these cytosolic proteases has been included in several studies 
with proteasome inhibitors-resistant epitopes, some have failed in finding a cytosolic 
protease responsible for the generation of a given epitope (Wherry et al., 2006). There is not 
a unique explanation for this: (1) The inhibition of the proteasome is not complete and the 
residual activity might be sufficient to generate the epitope (Wherry et al., 2006), (2) the 
altered pattern of the proteasomal activity caused by its inhibition (Garcia-Medel et al., 2011), 
might be able to generate the epitope and (3) other proteases, either resident in the 
secretory pathway, or non-described are responsible for the epitope generation when the 
proteasome activity is impaired. 
2.1.1.3. ER aminopeptidases. 
Compared to the cytosol, the ER shows a low proteolytic activity. Apart from the 
endoproteases signal peptidase (SP) and the signal peptide peptidase (SPP), there are other 
resident aminopeptidases in the ER that able to remove flanking residues from the antigenic 
peptide in its amino terminus. 
 ER aminopeptidases belong to the group of zinc-binding metallopeptidases. This 
subfamily has 3 members in humans, which are relevant to antigen processing. These are 
the enzymes ERAP1, ERAP2 and IRAP (insulin-regulated aminopeptidase). In mice, ERAAP 
acts as an ERAP1 homologous protein, whereas ERAP2 is not expressed. In contrast to 
IRAP, ERAP enzymes are inducible by IFNγ. Studies that use in vitro digestions show that 
ERAP1 trims optimally 9-to-16 aa-long peptides, and its products are rarely shorter than 8 or 
9 aa. This suggests that this ER aminopeptidase has evolved to generate peptides with a 
proper length for the binding to MHC class I molecules (Serwold et al., 2002; Saric et al., 
2002; York et al., 2002). This is consistent with TAP specificity to bind and translocate 
peptides to the ER, as well as with MHC-I allotypes specificity for peptide binding. About its 
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specificity, ERAP1 cleaves more efficiently from the precursor peptide big and hydrophobic 
residues either in the amino or carboxy termini. On the other hand, cleavage of charged or 
small hydrophobic residues is poorly efficient (Saveanu et al., 2005; Chang et al., 2005; 
Hearn et al., 2009). However, ERAP1 is not able to cleave peptides with proline in position 2. 
As a consequence these peptides, which come from larger cytosolic precursors, are 
accumulated in the ER. This successfully explains the preferential use of proline in position 2 
as binding motif of a considerable amount of MHC-I allotypes; whereas TAP is unable to 
transport these peptides (Serwold et al., 2001). ERAP1 trimming is also determined by inner 
positions 2, 5 and 7, having preference for hydrophobic or positively charged aa 
(Evnouchidou et al., 2008). 
 The resolution of ERAP1 crystallographic structure (Kochan et al., 2011; Nguyen et 
al., 2011) suggests that this enzyme undergoes conformational changes that would explain 
the low specificity for its substrate and the preference for large substrates. This structure fits 
better with the hypothesis of considering ERAP1 as a “molecular rule” (Chang et al., 2005) 
rather than the alternative “template“ model that proposed that the enzymatic action of 
ERAP1 occurred on peptides bound to murine MHC class I molecule  (Kanaseki et al., 2006). 
The “template” model has already been refuted by experiments in our laboratory with a 15 aa 
peptide from human immunodeficiency virus (HIV), a natural precursor that is found in 
infected cells and is trimmed by ERAP in vitro only when it is free from the murine MHC-I H-
2Ld molecule (Samino et al., 2006; Infantes et al., 2010). 
 It has been observed that CD8+ T lymphocytes repertoire is altered in ERAP-deficient 
mice, thus indicating that trimming of precursors is already occurring during CD8+ T 
lymphocytes selection in the thymus. However, although in these mice MHC-I molecules 
expression is diminished, this study failed in finding an effect in the response of CD8+ T 
lymphocytes against different viral antigens (Hammer et al., 2007). Different studies using 
interference RNA in cell culture have shown the contribution of ERAP1 as much as in the 
generation as in the destruction of different epitopes for their presentation on MHC-I to CTL 
(Serwold et al., 2002; York et al., 2002; Zervoudi et al., 2013). There are also evidences that 
ERAP deficiency compromises the cross-presentation of some particulate antigens (Yan et 
al., 2006; Firat et al., 2007a). 
 ERAP2 shows preference for substrates with basic residues either in the amino or 
carboxy termini. It can form dimeric complexes with ERAP1 increasing the efficiency in 
cleaving precursors (Saveanu et al., 2005). 
 The existence of ERAP inhibitors in cytomegalovirus shows the importance of this 
enzyme in antigen processing (Kim et al., 2011). It has also been possible to identify a CD8+ 
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T lymphocyte population that specifically recognizes the FL9 peptide presented by the non-
conventional Qa-1b MHC-I molecule, that is only generated when ERAAP activity is impaired 
(Nagarajan et al., 2012). 
 Several groups have studied the cleavage proteolytic activity in the cytosol and in the 
ER. Based on a bioinformatic study, Schatz et al. have analyzed the frequency of aa 
between positions N5 and N1, being N5 the initial most amino terminal residue of the amino-
extended peptide, of the precursors of more than 1500 known epitopes and they have 
identified the existence of an “amino-terminal processing motif”. Amino-extended precursors 
have aa like proline or tryptophan in the positions N4-N5. These precursors are previously 
trimmed in the cytosol and gain access to the ER with extensions of 1 to 3 aa like leucine or 
methionine or basic aa that would be removed by ER aminopeptidases. The relaxed 
cleavage specificities of cytosolic and ER aminopeptidases would fit with this amino-terminal 
degradation motif (Schatz et al., 2008). 
2.1.1.4. Carboxypeptidases in the secretory pathway. 
Until 2011, the study of the carboxypeptidase activity in the secretory pathway was 
based on data in rat cells (Powis et al., 1996), and it was assumed to bevery inefficient 
(Snyder et al., 1998) . It had also been demonstrated in murine and human cells using 
recombinant VACV harboring SIINFEKL extended or not in its carboxy terminus that the 
efficiency in epitope generation was limited 1,000-fold when SIINFEKL was C-terminally 
extended (Medina et al., 2009). 
However, there were clear evidences that in murine and human TAP-deficient cells 
some carboxy-trimming occurred in natural peptides, either coming from signal sequences 
(Henderson et al., 1992; Wei and Cresswell, 1992) or from entire proteins (Gil-Torregrosa et 
al., 1998). Finally, it has been recently described that ACE can generate the carboxy 
terminus of epitopes from peptides pre-processed by the proteasome. ACE-deficient mice 
show a new repertoire of unique epitopes, since some arise and some fade (Shen et al., 
2011). Indeed, the alteration of MHC-I-restricted peptide repertoire in the absence of ACE is 
sufficient to promote an immune response when wild type (WT) mice are inoculated with 
ACE-deficient cells (Gonzalez-Villalobos et al., 2013). In fact, the same authors also reported 
a protective effect in mice overexpressing ACE after immunization with a Polyoma virus 
epitope. 
Taken together, these studies show an emerging and significant role of ACE in the 
generation of MHC-I-restricted epitopes. 
16 
 
2.1.1.5. Vesicular endoproteases. 
Unlike the cytosol or lysosomes, the secretory pathway and vesicular compartments 
are poorly degradative. However, different endoproteases that participate in MHC-I antigen 
processing have been described (Table 1). 
 The signal peptidase (SP) is an enzyme that generates the mature form of secretory 
and some membrane proteins by recognizing and removing the signal sequence from 
proteins that translocate co-translationally into the ER. This is a pattern sequence that starts 
in the amino terminus with 1 to 5 basic residues, has a hydrophobic core with 7 to 15 aa 
followed by 3 to 7 polar aa and ends up with small and non-polar residues in the carboxy 
terminus. Cleaved signal sequences are short peptides that need little further trimming to 
bind MHC-I, but some examples that are trimmed on amino, carboxy or both termini have 
been described (Weinzierl et al., 2008; Suri et al., 2006; Oliveira et al., 2009). Several 
examples of TAP-independent epitopes generated by this enzyme have been described 
(Henderson et al., 1992; Wei and Cresswell, 1992; Bell et al., 2009), although there are also 
some epitopes that are destroyed (Schlosser et al., 2007). 
 Thanks to large-scale studies on the MHC-I ligand repertoire employing 
immunoproteomic and mass spectrometry techniques with non-infected cells, it is known that 
the signal sequence is the main source of TAP-independent ligands presented by HLA-A2 
and HLA-B51. The fact that HLA-A2 easily fits alanine in the carboxy terminal position 
explains that the signal peptidase can generate the exact carboxy terminus in most of the 
epitopes presented by this molecule (Weinzierl et al., 2008). In other MHC-I allotypes such 
as Kd, HLA-B51 or Qa-1b, further cleavage of the epitope is needed, either in the amino or in 
the carboxy termini (Weinzierl et al., 2008; Suri et al., 2006; Oliveira et al., 2009), thus 
implicating aminopeptidases like ERAP and carboxypeptidases like, maybe, ACE. 
 The signal peptide peptidase (SPP) is other endoprotease resident in the ER that 
cleaves in transmembrane domains and inside some signal peptides. It is involved in the 
processing and presentation of a proteasome and TAP-dependent (TAP-dep) epitope (Bland 
et al., 2003). 
 Two proprotein convertases located in the trans-Golgi network, furin and proprotein 
convertase 7 (PC7), have been found to be involved in the processing in the secretory 
pathway of some epitopes. 
 Furin is a proprotein convertase resident in the trans-Golgi network that mediates the 
maturation of many proproteins like peptidic hormones or viral glycoproteins. This enzyme 
cleaves preferentially after polybasic residues, having specificity for a RXR/KR motif. The 
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specific inhibitor dec-RVKR-cmk mimics the 4 aa conforming the binding motif to the 
protease. The inhibition of this protease with dec-RVKR-cmk blocks the presentation of the 
epitope 9pp89, generated from the viral construction rVACV sC-A9A to CTL by T2/Ld TAP-
deficient infected cells in a dose-dependent manner (Gil-Torregrosa et al., 1998; Gil-
Torregrosa et al., 2000). 
 As described in studies using DC, furin can generate around one third of all 
Kb/SIINFEKL complexes in TAP+ cells, showing that this protease takes part in antigen global 
presentation in the presence of TAP. Interestingly, furin generates Kb/SIINFEKL complexes 
in TAP-DC five times more efficiently than in TAP+DC. It has also been described that furin 
generates epitopes recognized by CD8+ T lymphocytes in TAP-deficient mice (Medina et al., 
2009). 
 PC7 is a serin-protease that shows a broad tissue distribution and is localized in the 
trans-Golgi network and in endocytic vesicles. Its cleavage substrates have arginine 
residues. It takes part in the stabilization of unstable cell surface MHC-I molecules in 
vesicular compartments derived from ER. This provides a second quality check-point for the 
loading of new peptides onto MHC molecules (Leonhardt et al., 2010). 
 Cathepsins are cystein or aspartic-proteases located in endolysosomal 
compartments. Together with furin, cathepsins are involved through a vacuolar TAP-
independent (TAP-ind) pathway in the generation of the epitope SIINFEKL from a chimeric 
fusion protein that links ovalbumin(OVA) and H-2Kb that is internalized from the cell surface 
(Tiwari et al., 2007). 
2.1.2. ABC transporters. 
The ATP-binding cassette (ABC) genes represent the largest family of 
transmembrane (TM) proteins. These proteins bind ATP to transport through extra- and 
intracellular membranes a wide diversity of compounds, such as metabolic products, lipids, 
drugs or peptides (Higgins, 2001; Childs and Ling, 1994). 
The ATP-binding domain, also known as nucleotide-binding domain (NBD), contains 
two characteristic binding motifs (Walker A and B) separated by 90-120 aa. The functional 
protein contains two transmembrane domains (TMD) and two NBDs, commonly arranged as 
N-TMD-NBD-TMD-NBD-C. Some of the ABC genes encode half transporters, harboring only 
one TMD and one NBD. These gene products need to form homo- or heterodimers to 
conform a functional transporter. The TMD contains 6-11 α-helixes that provide specificity for 
the substrate. The NBDs confer the energy to the transport through membranes. 
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Phylogenetic analysis of the 49 human ABC genes places them into 7 subfamilies of 
proteins: ABCA, ABCB, ABCC, ABCD, ABCE, ABCF and ABCG. ABC genes are expressed 
in all eukaryotic cells and are highly conserved between species. In the case of humans and 
mice, there is concordance between the two species, with some exceptions on the genes 
ABCB1 (duplication in mice, (Schinkel et al., 1994; Schinkel et al., 1997)); Abcg3 (present in 
mice but not in human, (Mickley et al., 2001)); ABCC11 (loss in mice, (Tammur et al., 2001); 
ABCA8 (duplication in mice (Annilo et al., 2003)) and ABCA10 (loss in mice, (Annilo et al., 
2003)). 
The ABCB family contains 11 genes, which are listed in Table 2. 
Gene name Alias 
Structure of 
the transporter 
Transport function References 
ABCB1 
PGY1, 
MDR 
Full 
Lipids, steroids and 
peptides (multidrug 
resistance) 
(Gottesman et 
al., 2002; 
Sharom, 
2011) 
ABCB2 TAP1 
Half 
(Heterodimer 
with TAP2) 
Peptides 
(Abele and 
Tampe, 1999) 
ABCB3 TAP2 
Half 
(Heterodimer 
with TAP1) 
Peptides 
(Abele and 
Tampe, 1999) 
ABCB4 PGY3 Full Phosphatidylcholine 
(Ruetz and 
Gros, 1994; 
van Helvoort 
et al., 1996) 
ABCB5 
 
Full Drugs 
(Frank et al., 
2005) 
ABCB6 MTABC3 
Half 
(Homodimer) 
Fe/S cluster 
(Mitsuhashi et 
al., 2000) 
ABCB7 
 
Half 
(Homodimer) 
Fe/S cluster 
(Csere et al., 
1998; 
Allikmets et 
al., 1999) 
ABCB8 MABC1 
Half 
(Homodimer) 
Ions 
(Ichikawa et 
al., 2012) 
ABCB9 TAPL 
Half 
(Homodimer) 
Peptides 
(Wolters et al., 
2005; Demirel 
et al., 2007) 
ABCB10 MTABC2 
Half 
(Homodimer) 
Unknown 
(Liesa et al., 
2012) 
ABCB11 
BSEP, 
SPGP 
Full Bile salts 
(Gerloff et al., 
1998) 
Table 2. List of genes of the ABCB subfamily and their functions. 
 Within this subfamily, only the heterodimer formed by TAP1 and TAP2 and TAPL are 
known to be involved in antigen presentation pathways (Abele and Tampe, 1999; Zhao et al., 
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2006). Of note, although ABCB1 is one of the best studied genes in the subfamily, its 
function has always been related to multidrug resistance, especially in tumor cells (Shepherd 
et al., 1993; Gottesman et al., 2002; Sharom, 2011). However, there are reports 
characterizing its capability to transport peptides through the plasma membrane (Sharma et 
al., 1992; Wang et al., 2016). 
2.1.2.1. TAP. 
 TAP is a heterodimer formed by the gene products TAP1 and TAP2. The transporter 
is located in the ER membrane and it translocates peptides in a range of 8-16 aa from the 
cytosol to the ER lumen, whereas the most efficient transport is restricted to 8-12 aa peptides 
(Androlewicz and Cresswell, 1994; van Endert et al., 1994).  
TAP1 and TAP2 contain 10 and 9 transmembrane helixes, respectively. The last 6 
helixes of each subunit form the core domain and are sufficient for peptide transport (Koch et 
al., 2004). The remaining 4 and 3 TM N-terminal domains are needed for the recruitment of 
tapasin and the rest of the components of the PLC. The peptide-binding region is localized in 
the last cytosolic loop and a 15-aa region within the last TM region of TAP1 and TAP2 
(Nijenhuis and Hammerling, 1996).The NBDs of both subunits are located in the cytosol, 
where they bind 2 ATP molecules by the Walker A and B loops from one subunit and the C 
loop from the other (Figure 1). The peptide binding step is ATP-independent (Androlewicz 
and Cresswell, 1994), whereas ATP hydrolysis is needed for the transport step (Neefjes et 
al., 1993). 
TAP affinity for the N-terminal aa of its substrates is different from the N-terminal 
affinity of MHC-I molecules, which suggests an important role of ER-resident 
aminopeptidases (van Endert et al., 1995; Serwold et al., 2002). The other selection criterion 
of TAP is the last C-terminal aa, which is preferably basic or hydrophobic (van Endert et al., 
1995). 
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Figure 1. Structure of TAP. 
The transporter TAP is formed by two subunits: TAP1 and TAP2. Each one of them contains 10 and 9 
TM domains respectively, as well as a nucleotide-binding domain (NBD) in the cytosolic side of the ER 
membrane. The 6 C-terminal helixes of both subunits form the core domain, sufficient for peptide 
transport. The remaining N-terminal TM domains are necessary for the recruitment of PLC 
components. The NBDs are crucial for ATP binding, which will allow the transport of peptides through 
membranes (Abele and Tampé, 2004). 
A correlation has been observed between the average length of the 
immunoproteasome products and TAP substrate selectivity, and also between TAP substrate 
sequences and MHC-I binding and T-lymphocyte recognition motifs (Uebel et al., 1997). This 
establishes a scenario in which different proteins participate in the selection and edition of 
the MHC-I ligands (Figure 2), suggesting a coevolution of TAP with the other components of 
the classical antigen presentation route. This makes this transporter a key factor in the 
classical MHC-I antigen presentation route. However, TAP can potentially transport many 
diverse peptides (lineal, ramified or modified, up to 40 aa) to the ER lumen (Uebel et al., 
1995; Gromme and Neefjes, 2002). These peptides need to be edited in the ER for the 
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anchor to different MHC-I allotypes, opening a broad spectrum of possibilities for non-
canonical antigen presentation routes. 
 
Figure 2. Proteins involved in the selection and edition of canonical MHC-I ligands. 
In the canonical route of MHC-I antigen presentation, proteasomes generate the C-terminus of the 
peptides which are transported to the ER by TAP. ER-resident aminopeptidases like ERAP1 and 
ERAP2 trim the N-terminus of the peptides and make them suitable to anchor to MHC-I molecules 
(Mester et al., 2011). 
 In certain conditions, like in viral infections (Mayerhofer and Tampe, 2015), tumors 
(Leone et al., 2013b) or TAP-deficient patients (Gadola et al., 2000), TAP is absent ant the 
only antigen presentation available is TAP-independent antigen presentation. In these 
situations, the CD8+T lymphocyte response may acquire a key role, since it is functional in 
the absence of TAP(Medina et al., 2009). 
2.1.2.2. TAPL. 
The TAP-like transporter (TAPL, ABCB9) is a homodimer that translocates peptides 
from the cytosol into the lumen of lysosomes. It presents certain homology with TAP1 and 
TAP2, with 39% of sequence identity with TAP1 and 41 % with TAP2, a similar identity to 
that between TAP1 and TAP2 (39 %) (Yamaguchi et al., 1999). Its structure is similar to 
TAP’s structure, with 10 α-helixes and one NBD. The 6 C-terminal helixes form the core of 
the transporter and show high identity with TAP1 and TAP2. The remaining 4 helixes show 
no identity to any protein in the databases. TAPL has a broad phylogenetic and tissue 
expression. It is speculated that TAPL gene is the ancestor of the ABCB family, since it is 
found in many taxa, even in invertebrates, and very conserved. Human and murine TAPL 
have a95 % identity (Zhang et al., 2000), while TAP1 and TAP2 show 75 % conservation 
between rodents and humans(Kobayashi et al., 2000). 
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Its tissue distribution is ubiquitous, although it has been found to be more abundant in 
testes, spinal cord and brain (Zhang et al., 2000). Of note, its expression is upregulated in 
the differentiation of monocytes to dendritic cells, although a role in MHC-I antigen 
presentation has been discarded so far, since its expression does not restore MHC-I surface 
expression in TAP1- or TAP2-deficient cells (Demirel et al., 2007). Although controversial in 
the beginning, TAPL subcellular localization is believed to be restricted to lysosomes, as 
established by immunofluorescence and subcellular fractionation (Zhang et al., 2000; 
Demirel et al., 2007; Demirel et al., 2010). 
In contrast to TAP, TAPL transports peptides with low affinity, making TAPL a very 
promiscuous transporter. Its substrates are in a range of 6-mer to 59-mer, with an optimum 
length of 23 aa. TAPL recognizes its peptides by the residues of both termini, preferring 
positively charged peptides with hydrophobic terminal residues, while negatively charged 
residues are disfavored (Wolters et al., 2005).  
Due to its ubiquous expression and high conservation in eukaryotes, TAPL has been 
proposed to be a housekeeping factor, preventing premature cell death by avoiding the 
accumulation of peptides in the cytosol (Bangert et al., 2011). However, its overexpression in 
professional antigen presenting cells such as macrophages and dendritic cells suggests a 
role for TAPL in antigen presentation (Demirel et al., 2007). It has been proposed to 
participate in autophagy, cross-presentation or negative selection of T-lymphocytes in the 
thymus (Bangert et al., 2011), but it hasn’t been observed any role in antigen presentation for 
TAPL so far. 
2.1.3. Class I major histocompatibility complex molecules. 
 The function of MHC-I molecules is to bind peptides and present them on the cell 
surface to allow the screening of all the cells in the organism by CD8+ T lymphocytes. The 
peptides displayed by MHC-I molecules on the cell surface are a representation of the inner 
status of a given cell. The recognition of viral or tumoral peptides by activated CD8+ T 
lymphocytes leads to the elimination of that cell. 
 The structure of the MHC-I molecules consists of a heterodimer formed by a variant α 
chain and a non-variant β2-microglobulin (β2m). The α chain has three domains: α1 and α2, 
which form the groove that harbors the ligand, and α3, that interacts non-covalently with 
β2m. The α3 also anchors to the plasma membrane and interacts with the CD8 co-receptor 
of T lymphocytes, while the α1 and α2 together with the ligand are recognized by the TCR. 
 MHC-I molecules are polygenic (there are several MHC-I genes, and they are 
different in every individual) and highly polymorphic (there are multiple alleles of each MHC-I 
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gene within the population). These two features make it very difficult for a pathogen to 
escape the immune system. In humans, the genes encoding the MHC are located in the 
chromosome 6, and it contains more than 200 genes. These genes are called human 
leukocyte antigen (HLA). In mice, these genes are located in chromosome 17 and they are 
called histocompatibility 2 (H-2). There are 3 main MHC-I genes in both species: HLA-A, 
HLA-B and HLA-C in humans; and H-2K, H-2D and H-2L in mice. Each of these genes 
encode the α chain of the respective MHC-I protein. The β2m gene is located in human 
chromosome 15 and in murine chromosome 2. In different species, like mice, different strains 
have different haplotypes, which makes impossible for CD8+ T lymphocytes from a given 
strain to recognize a different MHC-I/epitope complex from other strain of mice.  
 The binding of the ligand to the MHC-I groove is determined by much conserved 
positions in the MHC-I molecule. MHC-I molecules bind peptides of a small length-range, 
normally between 8 and 10 aa. However, it is possible for MHC-I molecules to bind larger 
peptides, protruding in the central region (Burrows et al., 2007), in the N-terminus (Samino et 
al., 2006) or in the C-terminus(Collins et al., 1994). Each allotype has its own conserved 
residues, which provides each allotype with different peptide specificities (Falk et al., 1991). 
The conserved motifs of each allotype are known for many human and mouse MHC-I 
molecules, which allows the prediction of epitopes of a given protein by different algorithms. 
The most popular tool for these predictions is SYFPEITHI (www.syphpeithi.de) (Rammensee 
et al., 1999). 
2.1.4. Cross-presentation. 
 Cross-presentation is defined as MHC-I presentation of antigen internalized by 
professional antigen presenting cells. In contrast, direct presentation deals with antigens 
synthesized within the cell. Cross-presentation plays a critical role in the CD8+ T lymphocyte 
response to pathogens, in tolerance and in autoimmunity (Kurts et al., 2010). Although most 
of the work concerning cross-presentation focuses on DCs, cells like macrophages, mast 
cells and epithelial cells can also cross-present antigens, being DCs the most efficient cross-
presenting cells (Heath and Carbone, 2001). As reviewed (van Endert P., 2016), it is 
currently impossible to outline a well-defined pathway for cross-presentation, as most of the 
studies concerning MHC-I endocytic pathway have been done in non-professional antigen 
presenting cells (Donaldson and Williams, 2009). Cross-presentation is useful for CD8+ T 
lymphocyte priming in three different contexts: (1) when pathogens do not infect directly DCs, 
the main APC that primes CD8+ T lymphocytes, (2) when pathogens interfere with the 
endogenous MHC-I processing pathway and (3) when infected DCs die or lose function 
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rapidly after infection and only the uptake of their fragments by non-infected DCs can prime 
CD8+ T lymphocytes. 
 It has been established that there are three potential pathways for cross-presentation 
(van Endert P., 2016).Antigens are internalized and can be translocated from endocytic 
vesicles to the cytosol. First, cytosolic peptides generated by proteasomes access the ER 
and bind nascent MHC-I molecules (Figure 3; 1). It has been shown that the ER-resident 
aminopeptidase ERAP1 is involved in cross-presentation of OVA/anti-OVA 
immunocomplexes while it is not required for soluble OVA cross-presentation (Firat et al., 
2007b). Second, cytosolic peptides can access endosomal compartments (Figure 3; 2) that 
receive ER components from ER-derived vesicles (Cebrian et al., 2011). IRAP, resident in 
endocytic compartments, has been implicated in the cross-presentation of OVA-coated 
beads (Huppa et al., 2010). The SNARE (Soluble N-ethylmaleimide-sensitive fusion protein-
Attachment protein Receptor) protein Sec22b, located on the cytosolic side of the ER 
membrane, is crucial in these two pathways since it mediates fusion of ER-derived vesicles 
with phagosomes (Cebrian et al., 2011). The last pathway does not require access of the 
internalized antigens to the cytosol and comprises the recycling of MHC-I molecules from the 
plasma membrane, involving lysosomal proteases (Figure 3; 3). 
Figure 3. Potential cross-
presentation pathways. 
After internalization of the 
antigen and translocation to 
cytosol, preprocessed 
cytosolic peptides access 
either the ER (1) or 
specialized compartments 
resulting from the fusion of 
phagosomes and ER-derived 
vesicles (2). A third pathway 
involves recycling MHC-I 
molecules from the plasma 
membrane (3)(van Endert P., 
2016). 
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2.1.5. Alternative direct antigen presentation routes. 
 Although TAP has a key role in MHC-I antigen presentation, it has been observed 
that some epitopes are presented on surface MHC-I molecules in the absence of TAP. 
These epitopes arise from many sources, such as viral proteins (Lee et al., 1996; Khanna et 
al., 1996; Sigal and Rock, 2000; Lautscham et al., 2001), endogenous proteins (Gueguen et 
al., 1994; Oliveira et al., 2011) or minigene products (Anderson et al., 1991; Raafat et al., 
2011). TAP1-/- mice show no defect in the expression of the TCR chains (Sandberg et al., 
1996), having the potential to recognize any epitope presented on MHC-I molecules. A broad 
and complete study of the contribution of TAP in the presentation of MHC-I-restricted 
epitopes encoded by a pathogen such as vaccinia virus has been done in our group, 
showing an unexpected high number of epitopes presented in VACV-infected dendritic cells 
lacking TAP: from 30 epitopes tested, 12 are presented in the absence of TAP (Lázaro S, 
PhD report). 
The contribution of the proteasome, another key player in MHC-I antigen 
presentation, to the generation of TAP-independent epitopes has been observed in some 
individual epitopes, but most of them do not require this protease to be processed (reviewed 
in (Del Val et al., 2013)). Both TAP-independent and proteasome-independent antigen 
presentation routes have been demonstrated as alternative pathways. It has been thought 
that both of them completely overlap, although that idea has been discarded with examples 
of TAP-independent epitopes that do require proteasome cleavage to be processed (Oliveira 
et al., 2014; Merzougui et al., 2011). A global study to determine how large this overlap is 
has not been done yet, and it is one of the goals of this work.  
2.2. Activation and function of CD8+ T lymphocytes. 
 Migratory dendritic cells (DC) are professional antigen-presenting cells (APC) that 
scan the organism seeking potential antigens. In the lymph nodes, these DC meet naïve 
CD8+ T lymphocytes. If these naïve CD8+ T lymphocytes recognize their specific antigen 
presented by the APC they get activated, a process known as priming. The recognized 
antigen can be originated from a self-protein expressed by the APC (direct presentation) or 
from an exogenous molecule endocytosed and processed by the APC (cross-presentation). 
If a CD8+ T lymphocyte is activated by a cross-presented epitope, the priming is called cross-
priming. 
 When they are activated, cytotoxic CD8+ T lymphocytes (CTL) undergo a clonal 
expansion, generating an antigen-specific population that leaves the lymph node and 
migrates to the infection site attracted by chemokines produced in the infected tissue. When 
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the CTL recognize a target infected cell, they induce apoptosis on the latter by two cytotoxic 
mechanisms:(1) The secretion of granules harboring the protein perforin releases this 
protein, which integrates in the plasma membrane of the infected cell forming pores. Those 
granules also contain granzymes, a family of serine proteases that induce cell death of the 
infected cell by activating the caspase cascade. (2) The interaction of the Fas ligand (FasL) 
expressed on the CD8+ T lymphocyte surface and its receptor Fas expressed on the infected 
cell surface. This interaction forms the death-inducing signaling complex (DISC) which 
triggers a signaling cascade in the infected cell that ultimately activates caspase 8. These 
proteases provoke the death of the infected cell. 
 When the population of infected cells is cleared, the number of CD8+ T lymphocytes is 
substantially reduced. Some of the CTL that got primed in the lymph nodes do not 
differentiate to effector CTL, but they acquire a memory CD8+ T lymphocyte phenotype, 
which allows a more rapid and specific response against a potential subsequent infection by 
the same pathogen. 
2.3. Vaccinia virus. 
 Vaccinia virus (VACV) is a large, enveloped double-stranded DNA virus that contains 
more than 200,000 base pairs that encode more than 200 proteins. It belongs to the 
Orthopoxvirus family, which includes a large number of viruses that infect different species 
like rabbits, camels or monkeys. Variola virus, the virus that causes smallpox in humans, 
also belongs to this family. It was eradicated during the 1970 decade by using VACV 
infections as a vaccine, which granted it its name. The high efficiency of VACV as a vaccine 
against the variola virus suggests a strong identity of antigenic peptides between these two 
viruses. The origin of VACV is still controversial, but it is thought to derive from the cowpox or 
the horsepox viruses (Baxby, 1977; Turner, 1982; Tulman et al., 2006). Its long history in 
vaccination has made VACV the model poxvirus in the laboratories. As a consequence, 
many strains of VACV arose. 
2.3.1. Virion structure. 
 The VACV mature virion (MV) has a barrel shaped structure with a nucleoprotein core 
flanked by protein structures called lateral bodies and an outer single bilayer lipoprotein 
envelope (Hollinshead et al., 1999) (Figure 4). Purified MVs contain at least 80 proteins 
(Chung et al., 2006). MV envelope seems to derive from the ER membrane modified with 
viral proteins (Moss, 2015). During VACV morphogenesis, the MV is wrapped by two more 
membranes coming either from the trans-Golgi or the endosomal vesicles (Hiller and Weber, 
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1985; Tooze et al., 1993). This is the extracellular virion (EV), which is released from the cell 
by exocytosis, unlike the MV which is released by cell lysis. Both virions have infective 
capacity. 
2.3.2. Life cycle 
 The first step to infect a cell is the entry of the virus. This step itself shows much 
variation among virus strains and cell types, observing from endocytosis of the viral particles 
to membrane fusion (Bengali et al., 2011; Bengali et al., 2012). The strain western reserve 
(WR) uses a low-pH endocytic pathway to enter the target cell (Bengali et al., 2009). When 
internalized, the nucleoprotein core is released to the cytoplasm, where the viral DNA is 
accessible for transcription of viral early genes. It is in the cytoplasm where viral factories are 
formed. These structures are cytoplasmic domains transiently surrounded by ER-derived 
cisternae (Tolonen et al., 2001) where viral DNA is concentrated. One characteristic and 
distinguishable structure of the viral factories is the crescent. The crescents are lamellar 
bodies derived from ER-cisternae(Husain et al., 2006; Maruri-Avidal et al., 2011) with a 
scaffold of trimers of the viral protein D13 (Szajner et al., 2005). After crescents are formed, 
viral DNA replication and virion assembly take place in these factories(Schramm and Locker, 
2005; de Castro et al., 2013).The crescent remains with the immature virion, D13 scaffold is 
degraded and core condensation progresses(Liu et al., 2014). The MV can be then wrapped 
by a double membrane coming from the trans-Golgi or the endosomal compartments to form 
the wrapped virion (WV) with three lipid bilayers. When leaving the cell by exocytosis, the 
WV loses one of the three bilayers and forms the EV, with two lipid bilayers (Figure 4). 
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Figure 4. VACV life cycle. 
The VACV virion enters the cell either by membrane fusion (for example, the strain Copenhagen) or by 
endocytosis (strain WR) (1). Then, the nucleoprotein core is released to the cytoplasm by the fusion of 
the virion membrane with the endocytic vesicle membrane (2). The transcription of early-expression 
genes takes place in the cytosol before the formation of viral factories (3). In the viral factories, DNA 
replication, the transcription of post-replicative-expression genes, the formation of the crescent (4) and 
the immature virion formation take place (5). D13 is degraded, core condensation progresses and the 
mature virion (MV) is released out of the viral factories (6). The MV is wrapped by double cellular 
membranes to form the wrapped virion (WV), which is transported to the plasma membrane to leave 
the cell by exocytosis, forming the extracellular virion (EV) (7). Adapted (Bidgood and Mercer, 2015).  
2.3.3. Gene expression kinetics. 
 Unlike most viruses, poxviruses replicate and transcribe their DNA in the cytosol 
rather than in the nucleus of the host cell. Their different open reading frames (ORFs) are 
closely spaced and temporally regulated. Early-expressed genes do not require DNA 
replication to be expressed, while intermediate- and late-expressed genes have a post-
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replicative (PR) expression. There is a cascade mechanism of regulation by which early 
genes are transcribed by late transcription factors, intermediate genes are transcribed by 
early transcription factors and late genes are transcribed by intermediate transcription factors 
(Baldick, Jr. and Moss, 1993; Davison and Moss, 1989; Keck et al., 1990) (Figure 5). Within 
the whole genome of VACV, 118 early genes, 53 intermediate genes and 33 late genes have 
been found (Yang et al., 2011). When the nucleoprotein core reaches the cytoplasm, early 
mRNAs contained in the virion are released into the cytoplasm, where they are translated. 
Early proteins can be divided according to their function into enzymatic proteins required for 
DNA replication (such as the DNA polymerase), transcription factors required for the 
transcription of intermediate genes and structural proteins, required for the morphogenesis of 
new virions (Figure 5). When the DNA is replicated, PR expression genes (intermediate and 
late) can be transcribed and translated. Treatments that impair this replication step inhibit the 
expression of both intermediate and late genes, like the treatment with the DNA replication 
inhibitor cytosine arabinoside (AraC) (Yang et al., 2011) or with proteasome inhibitors 
(Satheshkumar et al., 2009). The three categories of genes encode structural gene products 
necessary for the assembly of the immature virion (IV) (Figure 5). 
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Figure 5. Gene expression kinetics of VACV. 
After entry of the extracellular virion (EV) or mature virion (MV), the nucleoprotein core releases early 
mRNAs into the cytoplasm (1). Early mRNAs are translated, which allows the DNA replication in the 
viral factories by early gene products like DNA polymerase (2). Early transcription factors bind to the 
replicated DNA to transcribe intermediate genes (3). Likewise, intermediate transcription factors trigger 
the transcription of late genes (4). The structural proteins coming from early, intermediate and late 
genes together with replicated DNA form new immature virions (IV) (5) that will leave the viral factory 
as mature virions (MV). Based on (Moss, 2001). 
2.3.4. Immune response against VACV. 
 Although there are some studies in non-human primates regarding the immune 
response against VACV (Earl et al., 2004; Edghill-Smith et al., 2005), most of the work on 
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this issue has been done in mice. However, it must be considered that this species is not the 
natural host of the virus and that there are some differences in the infection between mice 
and humans, like the tropism of the virus or the affinity of the immunomodulatory proteins 
encoded by the virus. One example is the viral protein B8R, a soluble IFNγ receptor that 
binds human IFNγ but not murine IFNγ (Mossman et al., 1995; Alcami and Smith, 1995). This 
agrees with the observation that a rVACV lacking B8R shows similar virulence compared to 
the WT virus in infected mice (Verardi et al., 2001). 
 The innate cellular response against VACV comprises macrophages, neutrophils and 
natural killer (NK) cells. Macrophages have been found infiltrated in the site of infection in 
early days post-infection (d.p.i.) in mice (Reading and Smith, 2003; Jacobs et al., 2006). 
Although infection by VACV of macrophages isolated from mice has been observed to be 
abortive (Broder et al., 1994), it has been found that human monocyte-derived macrophages 
are permissive to VACV infection, and it is suggested that they participate in virus 
dissemination during the infection (Byrd et al., 2014). Whether there is a role for 
macrophages in the response against VACV and the nature of this response remains 
unknown. Neutrophils participate in the primary response against the virus by phagocytizing 
extracellular virions and degrading them (West et al., 1987; Jones, 1982).Since VACV can 
spread in a cell-to-cell way (Moss, 2006), the response against extracellular virions is not 
sufficient to fight a VACV infection. NK cells can develop a cytotoxic response against 
infected cells. These cells rapidly migrate to the site of VACV infection (Natuk and Welsh, 
1987). Murine and human NK cells show the capability to recognize and kill VACV-infected 
cells (Brutkiewicz et al., 1992), as well as in the human system (Chisholm and Reyburn, 
2006). Yet, the exact role of NK cells in primary VACV infections remains unclear. 
 The humoral response against VACV is an important component of the fight against 
the virus, as VACV-infected mice lacking B lymphocytes show viral titers increased up to 
100-fold when compared to WT infected mice(Xu et al., 2004). However, it has been 
observed that the antibody response against VACV prevents the dissemination of the virus, 
but it does not protect from mortality (Mota et al., 2011). 
 CD4+ and CD8+ T lymphocytes take part on the cellular adaptive response against 
VACV. There is no evidence that CD4+ T lymphocytes exhibit direct antiviral response, 
although mice lacking CD4+ T lymphocytes show increased viral titters (Xu et al., 2004). 
CD4+ T lymphocytes are an important source of IFNγ, a key cytokine for the activation of 
CD8+ T lymphocytes. There is also a correlation between the accumulation of CD4+ T 
lymphocytes and CD8+ T lymphocytes in the site in infection (Jacobs et al., 2006). CD4+ T 
lymphocytes also provide help for antibody response against VACV (Sette et al., 2008). CD8+ 
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T lymphocyte function appears to be vital for the protective response against VACV (Wherry 
et al., 2001; Amanna et al., 2006). It has been observed that direct antigen presentation is 
sufficient for the activation of VACV-specific CD8+ T lymphocytes (Xu et al., 2010), although 
for the non-replicative VACV strain MVA, cross-presentation appears to be crucial for this 
activation (Gasteiger et al., 2007). There is a large expansion of VACV-specific CD8+ T 
lymphocytes following infection (Harrington et al., 2002). When CD8+ T lymphocytes are 
depleted in vivo with antibody, CD8+-depleted VACV-infected mice show higher viral titers 
(from 2-fold to 10-fold) than control mice. However CD8+-depleted VACV-infected mice show 
higher weight loss than control mice, but all of them recover (Xu et al., 2004). This shows the 
existence of non-CD8+-mediated mechanisms in the protection against this virus. A similar 
result is obtained when mice lacking humoral response are infected, but when mice are 
deprived of both humoral and CD8+ T lymphocyte action, they never recover from VACV-
induced lesions (Xu et al., 2004). Therefore, there is a collaborative action of different 
immune mechanisms to control a VACV infection. 
2.3.5. Antigen presentation of VACV epitopes to CD8+ lymphocytes. 
Within 24 hours after an i.p. infection, VACV is spread throughout the organism (Lin 
et al., 2013). When the virus reaches its target cells, these are infected and they start to 
process antigens to present epitopes recognized by CD8+ T lymphocytes on their surface. It 
has been demonstrated that for 6 out of 8 epitopes studied, their source is the new synthesis 
of proteins (presumably DRiPs), instead of post-translational proteins, as the time in that the 
epitope is detected matches the time of detection of the corresponding protein(Croft et al., 
2013). The discovery of a VACV promoter that drives very early gene expression has led to 
the division of the early gene expression into E1.1 (very early) and E1.2 (early) (Wennier et 
al., 2013). This subclassification is supported by proteomics analyses that show that there 
are indeed two clusters of VACV genes, whose expression is resistant to the DNA replication 
inhibitor AraC (Yang et al., 2010; Croft et al., 2015). These analyses have also observed that 
there is a good correlation between gene transcription and protein detection and between 
gene expression and protein function, as early-expressed proteins are involved in DNA 
replication and host interaction, followed by genes involved in transcription and virion 
components, which are expressed at later times. 
Many techniques and approaches have been used to determine the VACV antigens 
recognized by CD8+ T lymphocytes, like predictive algorithms, chromatography and mass 
spectrometry, peptide libraries, etc. It has been proposed that mRNA levels can predict 
immunoprevalence of their corresponding proteins for CD8+ T lymphocyte response (Sette et 
al., 2009). However, there are many factor that determine the selection of antigens, such as 
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cellular processing, MHC-I binding, TCR recognition or immunomodulation (Sette et al., 
2009), and their prediction cannot be that simplistic (Croft et al., 2013). Until now, more than 
200 antigenic determinants for CD8+ T lymphocytes have been described in 7 different 
human allotypes (Oseroff et al., 2005; Pasquetto et al., 2005; Terajima et al., 2006) and 5 
murine allotypes together. In the BALB/c strain, 54 determinants have been described 
presented by the MHC-I molecules H-2Kd, H-2Ld and H-2Dd (Tscharke et al., 2006; Oseroff et 
al., 2008). In the C57BL/6 strain, 49 antigenic determinants have been found, presented by 
H-2Kb and H-2Db molecules (Tscharke et al., 2005; Moutaftsi et al., 2006). 
There is an immunodominance hierarchy determined by how abundant the CD8+ T 
lymphocyte response is against every single epitope (Moutaftsi et al., 2006). In this hierarchy 
in C57BL/6 mice, the epitope B8R accounts for about 25 % of the global response against 
VACV (Moutaftsi et al., 2006). This immunodominance can be altered depending on the 
route of administration of the virus, being the difference between B8R and the rest of the 
VACV epitopes more acute for systemic routes (i.v. and i.p.) (Lin et al., 2013). However, this 
hierarchy does not correlate with the protection hierarchy, obtained when C57BL/6 mice are 
vaccinated with a VACV epitope followed a VACV challenge, showing that 
immunodominance does not predict protective capacity of VACV epitopes (Moutaftsi et al., 
2009). The percentage of CD8+ T lymphocytes that recognize VACV epitopes in a VACV 
infection has been estimated to be 60 % of the total CD8+ lymphocyte population (Yuen et 
al., 2010).  
If mice are primed with a single VACV epitope, the CD8+ T lympchocyte response to it 
after a following VACV challenge is greatly enhanced. However, this enhanced response is 
only detected several weeks after the challenge (Russell et al., 2017). The priming with 
single epitopes does not alter the response to the rest of the viral epitopes, maintaining the 
immunodominance hierarchy (Russell et al., 2017). 
Of note, previous results in our lab show that, surprisingly, most of the VACV epitopes 
studied (15 out of 24), follow alternative antigen processing pathways, either TAP-
independent (12) or proteasome inhibitor-resistant (3). Also, most of the TAP-independent 
VACV epitopes characterized need proteasome cleavage, in contrast with the previously 
described in the bibliography (reviewed in (Del Val et al., 2013)). Altogether, this results show 
the high prevalence of antigen presentation pathways and therefore, the need of studying 
these alternative antigen presentation pathways in depth. 
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3. OBJECTIVES. 
 With the aim of studying TAP-independent (TAP-ind) viral antigen processing routes 
for the presentation by MHC-I molecules, we analyzed the response of CD8+ T lymphocytes 
from C57BL/6 mice against VACV-infected antigen presenting cells. We formulated the 
following objectives: 
1. To study the involvement of Sec22b in TAP-independent antigen cross-
presentation routes. 
2. To seek alternative transporters for TAP-independent VACV epitopes. 
3. To quantify the participation of proteasomes to the generation of VACV TAP-
independent epitopes. 
4. To analyze the role of non-proteasomal proteases in the generation of VACV 
epitopes. 
5. To study the physiological relevance of alternative antigen presentation pathways 
by analyzing the protective capacity of TAP-independent epitopes against a VACV 
infection in vivo. 
6. To find common and distinctive characteristics of TAP-independent VACV 
epitopes and/or potential precursors.  
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4. MATERIALS AND METHODS. 
4.1. Reagents 
4.1.1. Culture media. 
 The culture media used in this work are the following:  
-DMEM: Dulbecco-modified Eagle medium supplemented with ultraglutamine (Lonza) and 10 
% fetal bovine serum (FBS) (Sigma). 
-RPMI: Roswell Park Memorial Institute 1640 medium supplemented with ultraglutamine 
(Lonza), 5·10-5 M β-mercaptoethanol (Merck) and 10 % FBS. 
-α-MEM: Minimum essential medium α supplemented with ultraglutamine (Gibco), 5·10-5 M 
β-mercaptoethanol, 100 U/mL penicillin (Sigma), 100 U/mL streptomycin (Sigma), 10 µg/mL 
kanamycin (Sigma), 2.5 µg/mL amphotericin (Sigma) and 3 % FBS. 
-IMDM: Iscove's Modified Dulbecco's Medium (Sigma) supplemented with 2 mM L-alanyl-L-
glutamine (GlutaMAXTM, Gibco), 5·10-5 M β-mercaptoethanol, 10 % FBS, 100 U/mL penicillin 
(Sigma) and 100 U/mL streptomycin (Sigma) was used to culture BMDCs in the lentiviral 
transduction protocol. 
-Opti-MEM (Gibco) was used for transfection of HEK 293T cells. 
-Trypsin-EDTA: Trypsin (Sigma) diluted in EDTA 0.5 M pH 8 (Merck) was used to subculture 
adherent cells.  
-PBS: Phosphate-Buffered Saline: 137 mM NaCl, 1.5 mM KH2PO4, 8 mM Na2HPO4 and 2.7 
mM KCl. 
4.1.2. Chemical products. 
 Inorganic salts, acids, bases and inorganic compounds such as methanol or ethanol 
were mostly acquired from Merck. Sucrose and bovine serum albumin (BSA) were also 
supplied by Merck. 
 Paraformaldehyde (PFA) was supplied by Electron Microscopy Sciences. 
 Sigma provided dimethyl sulfoxide,β-mercaptoethanol, crystal violet, polybrene and 
brefeldin A (BFA). 
 Lipofectamine and PLUS reagent for cell transfection were supplied by Life 
Technologies. 
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The soluble protein OVA was acquired from Worthington Biochemical Corporation. 
 The protease inhibitors used are summarized in Table 6. Lactacystin was supplied by 
E. J. Corey (Harvard University, Cambridge, MA, U.S.A.), leucinthiol, N-benzyloxycarbonyl-
Val-Ala-Asp-fluoromethylketone (z-VAD-fmk) and decanoyl-Arg-Val-Lys-Arg-
chloromethylketone (dec-RVKR-cmk) were supplied by Bachem. Captopril was acquired 
from Sigma. 
 Recombinant human interleukin 2 (IL-2) was a kind gift from the NCI Preclinical 
Repository from the National Institutes of Health from the U.S.A. 
 The LIVE/DEAD Fixable Violet Dead Cell Stain Kit used to stain dead cells was 
supplied by ThermoFisher Scientific. 
 Granulocyte-macrophage colony-stimulating factor (GM-CSF) used to differentiate 
bone marrow precursors into dendritic cells in culture was a supernatant generated in the lab 
by culturing the J558 cell line. 
4.1.3. Antibodies. 
 The antibodies used in flow cytometry for the intracellular cytokine staining anti-
mouse CD8β.2 (53-5.8 clone) conjugated with fluorescein isothiocyanate and anti-mouse 
interferon-γ (XMG1.2 clone) conjugated with phycoerythrin, diluted respectively 1/300 and 
1/200 were supplied by Biolegend. The antibody anti-mouse H-2Kb conjugated with 
phycoerythrin was supplied by BD Biosciences and was diluted 1/300. The antibody anti-
CD11c conjugated with phycoerythrin was supplied by eBiosciences and the antibody anti-
GR1 conjugated with allophycocyanin was supplied by Biolegend and both were diluted 
1/300.  
 The primary antibodies used for the immunoblotting assay were the following: rabbit 
polyclonal anti-TAPL (D01P, Abnova) diluted 1/100, rabbit polyclonal anti-Tubulin (Sigma) 
diluted 1/500, rabbit polyclonal anti-Sec22b(Synaptic Systems) diluted 1/200, rabbit anti-
ERp57 (#2890 Ted H. Hansen (Harris et al., 2001)) diluted 1/200, rabbit anti-Tapasin (#2668 
Ted H. Hansen (Harris et al., 2001)) diluted 1/300 and mouse monoclonal anti-Actin (AC-40, 
Sigma) diluted 1/500. The secondary antibody used was goat anti-rabbit HRP 
(SouthernBiotech) diluted 1/5000. 
 CD8+ T lymphocytes were purified by negative selection using the mouse CD8+ T cell 
isolation Kit (MACS, Miltenyi Biotech). 
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4.1.4. Peptides. 
 The peptides were synthetized in an Applied Biosystems peptide synthesizer (model 
433A) and purified. The identity was confirmed by mass spectrometry in a Brücker 
Dalthonics MALDI-TOF equipment (model REFLEX) by Dr. D. López (Proteomics Unit, 
Centro Nacional de Microbiología, Instituto de Salud Carlos III,Madrid). Homogeneity of all 
peptides was checked by reversed-phase high resolution liquid chromatography in a 
BIOCAD equipment (Applera). 
 The synthetic peptides of VACV harbor the same aminoacidic sequences of the viral 
epitopes described (Moutaftsi et al., 2006). They were named after the coding gene. When 
more than one epitope in one protein is studied, the starting position of the epitope in the 
protein is indicated after the gene name. The one-letter code is used to name aa. The 
characteristics of the epitopes and the proteins they derive from are summarized later in                                      
Table 9.  
 The peptide SIINFEKL is harbored by the protein Ovalbumin (OVA) in the positions 
257-264. 
4.1.5. Cell lines and primary cells. 
-CV1 cells: Adherent fibroblasts from African green monkey kidney (ATCC: CCL-70). The 
culture medium used for these cells was DMEM. 
-HEK 293T: Homo sapiens embryonic kidney 293T cells containing the SV40 large T-antigen 
(ATCC: CRL-3216). They are adherent cells and were cultured in DMEM. 
 -RMA: A subline of the Rauscher virus-induced T cell lymphoma RBL-5 (H-2b) (Ljunggren 
and Karre, 1985). They grow in suspension and were cultured in DMEM. 
-RMA-S: A TAP2-deficient variant of the RMA cell line (Ljunggren et al., 1991; Zhou et al., 
1993). They are adherent and were cultured in DMEM. 
-B3Z: A T-cell hybridoma engineered to secrete β-galactosidase when its T-cell receptor 
engages an OVA257-264/K
b complex (Karttunen et al., 1992). They are non-adherent cells and 
were cultured in RPMI.  
-J558: A murine B lymphocyte myeloma (ATCC: TIB-6). They grow in suspension and were 
cultured in RPMI. They were used to obtain in their supernatant the GM-CSF that 
differentiates the bone marrow precursors into dendritic cells. 
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-Bone marrow-derived dendritic cells (BMDC): Bone marrows were obtained from femurs of 
healthy C57BL/6 mice. Bone marrow precursors were cultured in RPMI supplemented with 
10 % FBS, antibiotics and 10 % GM-CSF-enriched medium from J558 cells at a 
concentration of 1·106 cells/mL. The same volume of the same composition was added again 
3 and 6 days after the culture setting. Only the non-adherent cells were used for the 
experiments. For the vaccination assays, BMDC were matured incubating for 1 h in medium 
with 0.5 µg/mL of lipopolysaccharide (LPS). The CD11+/GR1- phenotype of the BMDC was 
checked by flow cytometry at day 7. 
-Monospecific polyclonal CD8+cytotoxic T lymphocytes (CTL): Their obtention and 
establishment is described in the CD8+ T lymphocyte section 4.4. They were cultured in α-
MEM supplemented with 3 % FBS. 
 All cells were cultured at 37 ºC in a 98% humidity atmosphere. Cells cultured with 
RPMI medium were cultured in a 5 % CO2 atmosphere. The rest of the cells were cultured in 
a 7 % CO2 atmosphere. 
4.1.6. Viruses. 
 The strain used in most of the infections was Western Reserve (WR). We used the 
recombinant VACV expressing full-length OVA (rVACV-OVA), derived from the strain WR for 
infection of BMDC in lactacystin assays to use the presentation of the epitope SIINFEKL as a 
control, since it has been reported that the presentation of Kb/SIINFEKL complexes in cells 
infected with recombinant VACV expressing full-length cytosolic OVA shows high sensitivity 
to this proteasome inhibitor (Antón et al., 1998). When the expression of the green 
fluorescent protein (GFP) was needed, we used the GFP-expressing recombinant vaccinia 
virus recombinant VACV expressing GFP (rVV-GFP). 
4.2. Mice. 
 The following strains of mice were used in this work: 
-C57BL/6JRccHsd (C57BL/6 from now on) used as a WT control (H-2b haplotype). 
-BALB/c (H-2d haplotype). 
-TAP1-/- mice (B6.129S2-Tap1tm1Arp/J; #002944, Jackson) (H-2b haplotype). In these mice, 
7 Kb from the TAP1 gene have been replaced by a neomycin resistance gene, 
encompassing about 80 % of the TAP1 protein-encoding region(van Kaer et al., 1992).Lack 
of expression of TAP1 leads to lack of assembly and degradation of TAP2(Furukawa et al., 
1999). 
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 Mice were immunized and infected intraperitoneally. For immunizations, BMDC were 
matured with LPS and incubated with 10-6 M synthetic peptide, and 1·106 of BMDC per 
peptide were injected, never exceeding 6·106BMDC per mouse. For infections with VACV, 
5·106plaque-forming units (PFU) of virus were administered. Mice were sacrificed in a CO2 
atmosphere. 
All mice were kept under pathogen-free conditions and studies were approved by the 
CSIC Animal Care Committee, with reference PROEX 302/14. All experiments were 
performed in accordance with relevant guidelines and regulations. 
4.3. Viral titration and viral infections. 
4.3.1. Production, purification and titration of virus. 
 Vaccinia viruses were grown in CV1 cells and purified from cell homogenates by 
ultracentrifugation in a sucrose cushion (Johnstone et al., 2004). Viral titration was assayed 
by serial dilutions, inoculation of CV1 cells and crystal violet staining 24 hours post-infection. 
The viral titer is expressed as plaque-forming units per milliliter (PFU/mL). 
4.3.2. Viral titration of organs. 
Spleens were harvested in 1 ml of PBS from mice three days after viral infection and 
kept frozen for no more than one week at -80ºC. They were thawed and homogenized by 
centrifugation with ceramic beads in a MagNA Lyser instrument (Roche) in a cold room at 4 
ºC. Ovaries were extracted and each frozen in 1 mL of PBS at -80 ºC. Homogenization was 
carried out by mechanic methods and 3 series of freeze-thaw cycles. The resulting lysates 
were tittered following the regular protocol starting at the minimum dilution 1/10. 
4.3.3. Viral infections. 
 BMDC were infected with VACV according to previously described protocols 
(Eisenlohr et al., 1992) with some modifications. Viral adsorption was performed at 4 ºC in 
PBS with 0.1 % BSA at a cell concentration of 1·107 cells/mL. The multiplicity of infection 
(m.o.i.) used in the experiments was in a range of 3-10, generally 5. After washing the cells, 
they were resuspended in culture medium at a concentration of 1·106 cells/mL and incubated 
at 37 ºC from 6 to 16 h in order to proceed with the infection.  
 In the case of inhibitor treatment, the infection never exceeded 6 h and the chemicals 
were added during the adsorption and added again at the desired concentration during the 
infection. 
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4.4. Effector cells. 
 Different sources of effector cells were used: 
-Purified CD8+ T lymphocytes: To study global viral antigen presentation using VACV-
infected BMDC, we purified CD8+ T lymphocytes from spleens of infected C57BL/6 mice. The 
purification is achieved by negative selection of CD8+ T lymphocytes using a cocktail of 
biotin-conjugated antibodies against CD4, CD11b, CD11c, CD19, CD45R (B220), CD49b 
(DX5), CD105, Anti-MHC-class II, Ter-119 and TCRγ/δ. The isolation of T cells is achieved 
by depletion of magnetically labeled cells. After the incubation with the cocktail, splenocytes 
were incubated with anti-biotin antibody-conjugated magnetic beads. Non-bound CD8+ T 
lymphocytes were collected by elution through a magnetized column. The process achieves 
a purification of at least 95 %. 
-Peritoneal exudate cells (PEC): To study the recognition of individual peptides after 
intraperitoneal vaccination with BMDC loaded with peptides followed by VACV challenge, 
PEC containing CD8+ T lymphocytes were used. One million PEC were incubated in the 
presence of BFA with a saturating concentration of each synthetic peptide for 6 h to stimulate 
their CD8+ T lymphocytes. 
-Monospecific Cytotoxic T Lymphocytes (CTL): To study the processing and presentation of 
individual epitopes, we generated polyclonal monospecific CTL lines from spleens from 
infected C57BL/6 mice as described before (López and Del Val, 1997). Briefly, mice were 
infected twice 21 days apart with 5·106PFU of VACV (WR or rVACV-OVA). Twenty-one days 
after the boost, spleens were harvested and splenocytes were cultured in multiwell plates in 
the presence of the synthetic peptide of interest in an optimized concentration, different for 
each peptide (from 10-8 to 10-10 M). Five days later, 25 U/mL IL-2 was added. The expansion 
and maintenance of the line was achieved by weekly stimulation with splenocytes loaded 
with the peptide of interest at the same concentration and with IL-2. 
-B3Z: To study the cross-presentation of OVA, we used the B3Z T-cell hybridoma that 
specifically and exclusively recognized the OVA257-264/K
b complex. 
4.5. Intracellular cytokine staining assay. 
 The intracellular cytokine staining assays (ICS) measure the activation of T 
lymphocytes after recognition of antigen presented by an infected cell or antigen presenting 
cell. They were performed according to previously described methods (Chen et al., 2000; 
Johnstone et al., 2004). In particular, PEC were stimulated with synthetic peptides in a 
saturating concentration (10-6 M) for 6 h and BFA was added for the last 5 h. Purified CD8+ T 
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lymphocytes were stimulated for 6 h in the presence of BFA since the beginning of the 
stimulation or 2 h after incubation with infected BMDC at serial Effector:Target (E:T) ratios in 
a range of 1:3 to 1:30. CTL were stimulated in the presence of BFA for 4 h with infected 
BMDC at an E:T ratio of 1:5 or with serial concentrations of synthetic peptides (10-11 to 10-8 
M) to test their sensitivity. After stimulation, CD8+ T lymphocytes were fixed, permeabilized 
and stained with anti-CD8-FITC and anti-IFNγ-PE antibodies. As an alternative for the 
fixating and permeabilizing reagents of the IntraStain kit for cytometry (Dako), we used a 
fixating solution containing PBS with 4 % PFA and a permeabilizing solution containing PBS 
with 4 % PFA, 0.1 % saponin and 1 % BSA. Cells were analyzed by flow cytometry using a 
FACSCalibur (BD Biosciences) equipment to detect the stained cells and the percentage of 
IFNγ+ cells within the CD8+ population was calculated using the FlowJo V10 software. 
4.6. Cross-presentation assay. 
 BMDC were cultured in flat-bottomed 96-well plates at a concentration of 1·105 
cells/200 µl. Three µm latex beads (17134, Polysciences) were coated with OVA and BSA at 
different proportions by incubating the beads with the proteins rotating at 4 ºC o.n. The 
following day, after washing, 200 beads/cell were added to the BMDC presenting cells and 
after a 5 h incubation at 37 ºC, cells were washed and fixed with 0.008 % glutaraldehyde in 
PBS by incubating at 4º C for 3 min. To stop the fixation, 0.4 M glycine was added. After 
several washes, 1·105OVA-specific B3Z T cells per well were added and recognition of the 
antigen was allowed by incubating at 37 ºC. After 16h, T cell activation was measured 
detecting β-galactosidase activity by optical density at 590nm (Victor Wallac, Perkin Elmer) 
using chlorophenol red-β-D-galactopyranoside (CPRG) in LacZ buffer (9 mM MgCl2, 0.125 % 
NP40 in PBS) as substrate for the reaction. 
4.7. Generation of lentiviral particles and lentiviral transduction. 
4.7.1. Generation of lentiviral particles. 
For the production of lentiviral particles harboring silencing RNA, we transfected HEK 
293T cells with plasmids encoding structural lentiviral proteins, control RNAs (or none) or 
silencing RNAs (Figure 6) (Table 3). HEK293T cells were cultured in plates starting at 1/10 
dilutions until they reached 80 % confluence. Per 55-cm2plate, 750 μl of Opti-MEM, 6 μg of 
packaging vectors (2 μg of pMD2.G, 2 μg of pMDLg/pRRE and 2 μg of pRSV-Rev), 8 μg of 
DNA of interest (pLKO.1, pLKO.1-shGFP, pLKO.1-shSec22b or pLKO.1-shTAPL) and 24 μl 
of PLUS reagent (which enhances transfection mediated by cationic lipids) were mixed. In 
parallel, 750 μl of Opti-MEM and 36 μl of lipofectamine per 55-cm2 plate were mixed. For 
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further specifications of the transfected plasmids, see Table 3 and Figure 6. After 5 min 
separate incubation at room temperature, all reagents were mixed and left 15 more min at 
room temperature.HEK293T cells were washed with PBS, and 3.5 mL of Opti-MEM plus 1.5 
mL of transfection mix were added to the cells and cultured overnight at 37ºC. The following 
day cells were washed and fresh DMEM medium was added and cells were incubated for 24 
h to produce and release lentiviral particles to the medium. Lentivirus-containing medium 
was then collected and filtered with 0.45 μm filters, aliquoted and frozen at -80ºC. 
 
Plasmid 
Gene 
expression 
GFP 
expression 
shRNA sequence Reference 
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pMD2-G Env No - 
(Dull et al., 
1998) 
pMDLg/pR
RE 
gag No - 
(Dull et al., 
1998) 
pRSV-
REV 
pol No - 
(Dull et al., 
1998) 
C
o
n
tr
o
l 
p
la
s
m
id
s
 
pLKO.1 
(SHC001) 
- Yes - 
(Moffat et 
al., 2006) 
pLKO.1-
shGFP 
(SHC002) 
shRNA anti-
GFP 
No 
CCGGCAACAAGATGAAGAGCACCAACT
CGAGTTGGTGCTCTTCATCTTGTTGTTT
TT 
(Moffat et 
al., 2006) 
S
il
e
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c
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g
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pLKO.1-
shTAPL 
shRNA anti-
TAPL 
Yes 
CCGGCCGTGTATTGTTGGATGGCAACT
CGAGTTGCCATCCAACAATACACGGTT
TTTG 
(Moffat et 
al., 2006) 
pLKO.1-
shSec22b 
shRNA anti-
Sec22b 
No 
CCGGCCCTATTCCTTCATCGAGTTTCT
CGAGAAACTCGATGAAGGAATAGGGTT
TTTG 
(Moffat et 
al., 2006) 
Table 3. List of plasmids used in this work. 
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Description Vector Element 
U6 Human U6 promoter. It drives RNA Polymerase III transcription for generation of 
shRNA transcripts. 
cPPT Central polypurine tract. It improves transduction efficiency by facilitating 
nuclear import of the vector’s preintegration complex in the transduced cells. 
hPGK Human phosphoglycerate kinase promoter. It grants constitutive expression of 
puroR. 
puroR Puromycin resistance gene for selection of pLKO.1 plasmid in mammalian cells. 
It encodes puromycin N-acetyl transferase, which acetylates puromycin, 
inactivating it. 
SIN/3’LTR 3’ Self-inactivating long terminal repeat. 
f1 ori f1 bacterial origin of replication. 
ampR Ampicillin resistance gene for selection of pLKO.1 plasmid in bacterial cells. 
pUC ori pUC bacterial origin of replication. 
RSV/5’LTR 5’ long terminal repeat. 
(Ψ) Psi RNA packaging signal. 
RRE Rev response element. 
Figure 6. Map and elements description of the pLKO.1 negative control vector. 
All the plasmids based in pLKO.1 share this common structure. In the case of harboring a shRNA 
sequence, this is located right after the U6 promoter.  
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4.7.2. Lentiviral transduction 
4.7.2.1.BMDC 
Two hundred thousand BMDC, harvested 3 days after extraction of bone marrow 
cells, were cultured in flat-bottomed 96-well plates in 200 μl of IMDM medium supplemented 
with 20 ng/mL of GM-CSF. Three days later, plates were centrifuged for 2 min at 2200 r.p.m. 
and the medium was collected and stored. Fifteen microliters of lentiviral particles were 
added to each well together with 35 μl of IMDM medium supplemented with polybrene at a 
final concentration of 8 μl/mL. Plates were then centrifuged at 37ºC at 2200 r.p.m. for 90 min. 
Lentiviral particles were removed and 100 μl of previously stored conditioned IMDM medium 
was added to the wells together with 100 μl of fresh IMDM medium. Three days later positive 
selection was carried out by adding puromycin 5 μg/mL for 2 days. 
4.7.2.2. RMA and RMA-S 
One hundred thousand cells were cultured in flat-bottomed96-well plates in 200 μl of 
DMEM medium. Plates were centrifuged at 2200 r.p.m. for 2 min and medium was 
discarded. Ten microliters of lentiviral particles together with 10 μl of fresh DMEM medium 
supplemented with polybrene at a final concentration of 8 μl/mL were added to each well. 
Plates were centrifuged at 37 ºC at 1200 r.p.m. for 45 min, then 80 μl of medium was added 
and cells were incubated for 6 h at 37ºC. Cells were again centrifuged and lentivirus-
containing medium was replaced by 100 μl of fresh medium. Two days later positive 
selection was carried out. 
The differences in the trandsduction protocol between BMDC and RMA or RMA-S are 
due to the difference growth rate (fewer RMA or RMA-S cells are cultured in the beginning of 
the protocol), the need of maturation factors for BMDC (three-days enriched medium is not 
discarded for BMDC) and the difference in lentiviral transduction success (smaller volume 
quantities of lentiviral particles are used for RMA or RMA-S cells and the second 
centrifugation does not need to be as long as it does for BMDC). 
4.8. Western blotting 
4.8.1. Protein extraction. 
 One million BMDC or RMA cells were pelleted by centrifugation and lysed in radio 
immunoprecipitation assay buffer (RIPA: 150 mM sodium chloride, 1 % NP-40, 0.5 % sodium 
deoxycholate, 0.1 % sodium dodecyl sulfate (SDS), 50 mM Tris-HCl pH 8.0) with Complete 
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protease inhibitors (Roche) preheated at 95 ºC. Cells were lysed at 95 ºC for 15 min and 
DNA was discarded by centrifuging the lysate at 15000 r.p.m. for 15 min. at R.T. The 
supernatant was collected and protein was quantified using the BioRad Bradford Protein 
Assay kit. Sample buffer (60 mM Tris-HCl pH 6.8, 10 % glycerol, 1.25 % β-mercaptoethanol, 
0.01 % bromophenol blue (w/v), 2 % SDS) was added to each sample in a dilution 1/6 
(sample buffer/sample) and samples were boiled at 95 ºC for 5 min to denature the proteins. 
Samples were stored at -20 ºC. 
4.8.2. Immunoblotting. 
Thirty µg of protein samples were loaded onto10% acrylamide SDS-PAGE gels, and 
proteins were transferred for 2.5 h at 4 ºC to nitrocellulose membranes (Hybond-ECL, GE 
Healthcare) in a tank system (BioRad). Membranes were blocked in a 5 % powder milk in 
PBS-Tween 0.1 % solution overnight at 4 ºC, washed and incubated with primary antibodies 
for 1 h at 4 ºC. Primary antibodies used for immunoblotting are summarized in the Antibodies 
section 4.1.3. After washing the primary antibody with PBS-Tween 0.1 % three times, the 
membranes were incubated with the secondary antibody for 1 h at 4 ºC. The membranes 
were developed by chemiluminescence (ECL, GE Healthcare). 
4.9. RNA quantification. 
4.9.1. RNA extraction. 
RNA samples were extracted from RMA and RMA-S cells with TRIzol Reagent (Life 
Techonologies). Briefly, cells were lysed in TRIzol Reagent, mixed with chloroform and 
centrifuged. The aqueous phase containing the RNA was collected and placed in a new tube. 
Isopropanol was added and the sample was centrifuged again to precipitate the RNA. After 
precipitation, the RNA pellet was washed with 75 % ethanol and air dried. The RNA was 
resuspended in RNase-free water, heated at 55 ºC for 10 min, and stored at -80 ºC. RNA 
purity and concentration were determined by using a Nanodrop ND-1000 (Thermo Scientific). 
RNA integrity and DNA contamination were determined by agarose gels and a Bioanalyzer 
Agilent 2100 (Agilent). 
4.9.2. Quantitative reverse transcription PCR (RT-qPCR). 
RT-qPCR was performed in intron-spanning assays using the primers listed in Table 
4 by the Genomics Facility of the Centro de Biología Molecular Severo Ochoa. Primers were 
designed using the software ProbeFinder and primer specificity was checked by performing 
BLAST using the NCBI tool Primer-BLAST. 
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 Gene  Primers 
 
 
 Forward Reverse 
N
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e
r 
g
e
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e
s
 β2m  TACATACGCCTGCAGAGTTAAGCA TGATCACATGTCTCGATCCCAG 
Dgcr8  GGGGTTCCTTACTACGCATGT CACACTCTTGTCAGAGGTCTCCT 
Gapdh  CACCACCAACTGCTTAGCCC TGTGGTCATGAGCCCTTCC 
Map2k2  CAGACTTCCAGGAGTTTGTGAAT CTTGATGAAGGCGTGGTTC 
Tap1  GTGCACAGAGAGGTGTTTCG CAGTCACCCGAGATGTGATG 
Tbp  CCACAGGGCGCCATGA GCTGTGGAGTAAGTCCTGTGCC 
Ywhaz  TTACTTGGCCGAGGTTGCT TGCTGTGACTGGTCCACAAT 
G
e
n
e
s
 o
f 
in
te
re
s
t 
Sec22b 
Design 1 AGAAGAAAGGCCCAGCTTAAA TTGGGAACGCATAGACAAAGT 
Design 2 TGGTGGCCAATATTGAAGAAG TCAAAGGCTAACAATTTGTCCA 
Design 3 TGGTTTTGTGTGAAGCTGCC GCATTGGATTCAAAGGCTAACAA 
Abcb9 
(TAPL) 
Design 1 CCGTGTATTGTTGGATGG AGATGTTGTCTGTGATGGA 
Design 2 CCCACACACAGGTCCTACAG CGTGTGTGAACATCCTGGA 
Design 3 CCTGGAGAACTTCTACCCTCTGC GGCGCCTATGACCACAAGTAC 
Table 4. Primers used for RT-qPCR. 
 Three different primer designs were developed for genes Sec22b and TAPL to avoid 
false positive results due to the location of the primers (Shepard et al., 2005). For both genes 
we designed three intron-spanning and non intro-spanning pairs of primers in different 
regions of the genes (Figure 7). 
 
 
Figure 7. Scheme of the position of the primers used in the RT-qPCR. 
The maps of the genes Sec22b and TAPL are extracted from Ensembl. Black thick lines indicate the 
location of the interfered zone. Designs of primers to amplify three different gene regions of Sec22b or 
TAPL are indicated by arrows. Vertical lines indicate the position of introns. 
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 The retrotranscriptase reactions were performed manually using the retrotranscription 
kit iScript cDNA Synthesis kit (BioRad, 170-8891) containing random primers and oligo-dT, 
following manufacturer’s instructions. For the reaction, 1 μg of RNA in a final volume of 20 µl 
was used. 
 Amplification was performed using the master mix Power Sybr Green (Applied 
Biosystems) following the amplification protocol: 10´ at 95ºC + (15” at 95ºC + 1´ at 60ºC) x 40 
+ 5’’ at 60ºC + 5’’ at 95ºC. Fluorescence acquisition was performed at the end of the 
elongation step (1’ at 60 ºC) during the amplification and during all the temperature slope in 
the melting cycle (5’’ at 60 ºC). The specificity of the amplification product was checked by 
monitoring a denaturing cycle (from 60 to 95 ºC) on the final amplified product. Only one 
product was observed for all the genes analyzed, verifying the specificity of the amplification 
product. 
 Data were processed using the software GenEx v5.4.4, which performs the following 
processing steps: 1. Primers efficiency correction; 2. Calculation of the mean of triplicates of 
the qPCR; 3. Normalization of the data (2-ΔCt) (Ct, “threshold cycle”: the cycle number at 
which the fluorescence signal crosses the threshold at which it occurs significant and specific 
amplification), using as a reference the expression of the gene Map2k2 (established as one 
of the most stable genes included in the experiment by the software NormFinder), correcting 
the variability between experiments and 4. Relative quantification of each gene in the sample 
of interest (pLKO.1-shSec22b and pLKO.1-shTAPL) in relation to the expression of the same 
gene in the calibrating sample (pLKO.1 or pLKO.1-shGFP) (2-ΔΔCt) when we analyzed 
silencing of genes Sec22b and TAPL after transduction with lentiviral particles. 
4.10. Statistical analyses. 
Analyses of the data are based in mean values and errors expressed as standard 
deviation (SD) for RT-qPCR data or standard error of the mean (SEM) for the rest of the 
experiments. To compare means between different groups of data, unpaired two-tailed t tests 
were performed. In the case of the experiments measuring viral titer, Mann-Whitney 
nonparametric t-tests were performed due to a non-Gaussian distribution of the data. This 
test compares differences between medians. The significance of the difference was given by 
the p value (***, p value ≤ 0.001; **, p value ≤ 0.01; *, p value ≤ 0.05; non-significant, p value 
> 0.05). The software used to perform statistical analyses was Graph Pad Prism 5. 
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5. RESULTS. 
5.1. Involvement of transporters and vesicular transport involved in TAP-
independent antigen presentation. 
 The ATP-binding cassette (ABC) family is a family of transporters that includes TAP 
that use the energy of ATP to transport a vast diversity of molecules (Theodoulou and Kerr, 
2015; Zolnerciks et al., 2011; Hinz and Tampe, 2012). Cells count on many transporters 
within the ABC family, each of them with different transport functions (Hickman et al., 2013; 
Sasaki et al., 2011; Looker et al., 2015a; Zhao et al., 2006). One possible explanation to 
TAP-independent antigen processing is that it may exist another peptide transporter that 
could transport some MHC-I ligands or precursors to MHC-I compartments, and therefore 
bypass TAP. We proposed one of the members of the TAP family, Abcb9 (also known as 
TAP-like or TAPL), as a candidate alternative transporter of MHC-I binding peptides, since it 
is known to participate in the transport of MHC-II-binding peptides (Zhao et al., 2006). 
 We also aimed to know more about the vesicles involved in this kind of alternative 
routes using the SNARE proteins as a tool to study vesicle trafficking. The SNARE Sec22b 
protein is expressed in the ER membrane and it is involved in ER to Golgi transport (Gordon 
et al., 2010)as well as in the fusion of ER-derived vesicles to phagosomes(Becker et al., 
2005).It has been implicated in TAP-dependent antigen cross-presentation (Cebrian et al., 
2011). Therefore, assessing whether TAP-independent cross-presentation is dependent on 
Sec22b or not, would tell us if TAP-independent cross-presentation routes depend on the ER 
and ER-derived compartments or not. 
 To study the possible involvement of TAPL and Sec22b in TAP-independent viral 
antigen processing, we generated lentiviral particles harboring plasmids with shRNA 
sequences to silence the expression of either the transporter TAPL, the SNARE protein 
Sec22b or none of them as a negative control. 
5.1.1. Effect of Sec22b silencing on cross-presentation of OVA-coated beads. 
To study the involvement of the SNARE protein Sec22b on TAP-independent cross-
presentation by BMDC, we generated lentiviral particles harboring either an RNA 
complementary to the Sec22b transcript (shSec22) or a RNA anti GFP as a negative control. 
We transduced C57BL/6 and TAP1-/- BMDC with the resulting lentiviral particles and checked 
the effect of shSec22b RNA on the expression of Sec22b protein and the results show a 
specific decrease in Sec22b protein levels in shSec22b-transduced BMDC (Figure 8). 
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C57BL/6 and TAP1
-/-
 BMDC were transduced with 
lentiviral particles harboring either antiGFP RNA or 
shSec22b RNA. Five days later, immunoblotting with 
Sec22b, ERp57, Tapasin and Actin antibodies was 
performed. 
 
 
 
  
It was already described that cross-presentation of OVA from OVA-coated beads by 
C57BL/6 BMDC was dependent on Sec22b, possibly due to its role in ER-derived vesicle 
fusion to phagosomes (Cebrian et al., 2011). We wondered if the previously described OVA-
coated beads proteasome-dependent and TAP-independent cross-presentation (Merzougui 
et al., 2011) also needed Sec22b-dependent PLC supply from the ER to the phagosomes 
and therefore, if it was Sec22b dependent. If TAP-independent epitopes access the ER or 
ER-derived compartments, TAP-independent cross-presentation would need Sec22b 
function. On the other hand, Sec22b-independency would mean either that the presentation 
of the epitope does not require the components of the ER or that there is some undescribed 
Sec22b-independent anterograde transport from the ER. 
 The results reproduce the previously described Sec22b dependency on cross-
presentation by C57BL/6 BMDC but they show no need of this protein for cross-presentation 
of OVA-coated beads byTAP1-/- BMDC (Figure 9). 
Figure 8. Sec22b protein levels decrease 
after specific shRNA lentiviral transduction 
in BMDC. 
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Figure 9. OVA-coated beads cross-presentation is Sec22b-dependent in C57BL/6 
BMDC but Sec22b-independent in TAP1-/- BMDC. 
C57BL/6 and TAP1
-/-
BMDC were transduced with lentiviral particles harboring an antiGFP RNA or a 
shSec22b RNA. The effect of silencing Sec22b on OVA cross-presentation to B3Z T cells was 
analyzed by incubating BMDC with 3 μm beads coated with different quantities of the antigen and the 
protein BSA as a coating control. After incubation with the beads, BMDC were co-cultured with B3Z T-
cell hybridoma. T cell activation was measured as LacZ activity of B3Z T-cell hybridoma using a 
spectrophotometer and data were relativized to the highest value of activation in each experiment. 
Mean activation values and SD values for three independent experiments are shown (A). Data 
corresponding to beads loaded only with OVA from three previous experiments were statistically 
analyzed by a two-tailed t-test (B). 
5.1.2. Use of lentiviral vectors to silence Sec22b and TAPL gene expression. 
 After knowing the lack of involvement of Sec22b on TAP-independent OVA cross-
presentation by BMDC, we wanted to know if transport mediated by Sec22b was 
participating in TAP-independent direct presentation of viral antigens. Also, we wanted to 
assess the possible role of the transporter TAPL in this kind of direct antigen presentation. 
We used lentiviral particles in the attempt to silence these genes separately. We changed the 
negative control plasmid from pLKO.1-shGFP to pLKO.1 expressing GFP and transfected 
HEK 293T cells with lentiviral packaging plasmids and pLKO.1 and pLKO.1-shTAPL, both 
GFP and puromycin resistance expressing plasmids (Table 3).We confirmed the success of 
the transfection by GFP expression (Figure 10). The resulting lentiviral particles were 
collected and used to transduce C57BL/6 and TAP1-/- (BMDC) and lymphoma-derived RMA 
or RMA-S cells. RMA-S cells area mutant cell line derived from RMA that lack the expression 
of TAP2 (Ljunggren et al., 1991; Zhou et al., 1993). To select the successfully transduced 
cells, we added puromycin to the cell culture and percentage of living cells and GFP 
expression were tracked over time (Figure 11). 
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HEK293T cells were transfected with plasmids 
pLKO.1 (black empty histogram), pLKO.1-shTAPL 
(grey empty histogram) or non-transfected (black 
filled histogram). Forty-eight hours after transfection, 
GFP expression in HEK293T cells was measured by 
flow cytometry. Numbers show the values of mean 
GPF fluorescence intensity. 
 
 
 
Figure 11. Cell survival and GFP expression after lentiviral transduction of RMA cells 
and BMDC. 
Figure 10. HEK293T cells are efficiently 
transfected. 
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RMA cells and BMDC were transduced with lentiviral particles harboring a shTAPL RNA (shTAPL) or 
only the vehicle plasmid (pLKO.1), both expressing GFP. Three days later, puromycin was added for 
selection of transduced cells. The percentage of living cells (A, C) and GFP expression (B, D) of RMA 
cells (A, B) and BMDC (C, D) was measured by flow cytometry at different days. The kinetics of GFP 
expression is calculated as the fold increase of the mean fluorescence of transduced cells to the 
untransduced control (dotted line) for RMA (B) and shown at five days for BMDC (untransduced 
control, filled histogram; LV-pLKO.1, empty histogram) (D). 
 Although the efficiency of transduction was low for lymphoma cells, we chose these 
as a model to perform our experiments. First, we had a short time frame for testing with CTL 
since BMDC greatly lose their capacity to be infected by VACV after ten days in culture 
(transduction and selection protocol alone takes eight days). Second, there was a lack of 
reproducibility in the lentiviral transduction of BMDC. Third, sensitive and specific CTL lines 
were frequently unavailable when needed. 
To establish non-transient transduced lymphoma cell lines (that did not lose infectivity 
over time) we had to wait for more than 30 days to have enough control, shTAPL and 
shSec22b in both RMA and RMA-S cells to be able to check gene expression and perform 
further experiments. As we did not succeed in stablishing a RMA cell line transduced with 
control plasmid pLKO.1-shGFP, we used pLKO.1 which did not express any shRNA (Table 
3) as a negative control for experiments with RMA cells. 
 To check if the expression of the proteins of interest was reduced, we performed 
immunoblotting of RMA cells with confusing results, since we obtained two different bands 
when detecting TAPL, one with the expected molecular weight (75 KDa) and one with a non-
expected weight (50 KDa). The expected band did not decrease in shTAPL-transduced cells 
while the non-expected band did decrease in the same cells (Figure 12). Immunoblotting of 
Sec22b in RMA and RMA-S cells resulted in several bands around the expected molecular 
weight and none of them decreasing after shSec22 transduction (data not shown). 
Five weeks after lentiviral transduction, 
proteins were extracted from RMA cells and 
an immunoblotting to detect TAPL was 
performed. Tubulin was immunoblotted as 
a loading control. 
Figure 12. Anti-TAPL immunoblotting 
after shTAPL lentiviral transduction of 
RMA cells. 
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We tried another method to measure gene expression. RT-qPCR of two individual 
samples of the same cells was performed to measure the expression of TAPL and Sec22b, 
with three different pairs of primers for each gene. Also, to have several candidates to 
normalize the data, primers for Ywhaz, Gapdh, Tap1, Dgcr8, β2m, Tbp and Map2k2 genes 
were also included in the experiment. After the experiments, we chose Map2k2 as the best 
candidate for normalization due to its highly stable expression shown. The RQ values (RQ = 
relative quantification = 2-∆∆Ct) show no inhibition of the expression of any of the genes 
neither in RMA nor in RMA-S cells (Figure 13).These results agree with the expression of 
GFP in transduced cells, which is lost over time. On the other hand, puromycin resistance is 
not lost in transduced cells, probably due to a selective pressure that did not affect the 
expression of GFP. We think that the unlikely dissociation between GFP expression and 
puromycin resistance happened because of the survival of cells after eventual loss of GFP 
expression, while eventual loss of puromycin resistance expression would lead to cell death 
in the presence of puromycin. 
Two individual RNA samples from RMA 
(A) and RMA-S (B) cells transduced with 
each of the three indicated lentiviruses 
were used to measure the expression of 
the genes Sec22b and TAPL by RT-
qPCR using three different pairs of 
primers for each of them. Gene 
expression is relativized using the ΔΔCt 
method (Livak and Schmittgen, 2001). 
Mean and SD values are shown. 
Triplicates of the RT-qPCR for each 
sample were performed. 
  
 
 
Figure 13. Detection of the 
expression of Sec22b and TAPL 
genes in RMA and RMA-S cells by 
RT-qPCR after lentiviral 
transduction. 
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Since we failed in silencing any of the genes in RMA and RMA-S cells, we could not 
perform further experiments to study the possible involvement of TAPL and Sec22b in TAP-
independent direct antigen presentation. 
We analyzed the data corresponding to the cells transduced with no shRNA to obtain 
a side result checking if the expression of all the genes included in the RT-qPCR was 
relevantly different in RMA compared with RMA-S cells. The results show a very similar 
profile for the two kind of cells except for the transporters TAPL and TAP1and the gene 
Dgcr8, involved in the biogenesis of microRNA, which was higher in RMA cells (2.46-fold± 
0.58 for TAPL and 2.67-fold± 0.25 for TAP1) (Figure 14). 
 
 
RNA samples were extracted from RMA and RMA-S cells transduced with lentiviral particles with no 
shRNA to perform RT-qPCR for several genes (Ywhaz: Tryptophan 5-Monooxygenase Activation 
Protein; Gapdh: Glyceraldehyde-3-Phosphate Dehydrogenase; Tap1: Transporter associated with 
antigen processing 1; Dgcr8: DiGeorge Syndrome Critical Region Gene 8; β2m: beta 2 microglobulin; 
Tbp: TATA Box Binding Protein). For the genes Sec22b and TAPL, three different pairs of primers 
were designed and included in the experiment. Two individual RNA samples for each cell type were 
included and triplicates for each sample were performed. The expression of the gene Map2k2 was 
used as a normalizer and the relative quantity mean and SD values of the indicated genes are shown.  
 Finally, we aimed to check if TAP-independent viral antigen presentation routes are 
equally efficient in our two models of presenting cells, primary BMDC and the lymphoma cell 
line RMA. We performed ICS assays using purified CD8+ T lymphocytes from VACV-infected 
C57BL/6 mice as effector cells and either VACV-infected C57BL/6 BMDC or VACV-infected 
Figure 14. Comparison of RMA and RMA-S gene expression. 
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RMA cells as antigen presenting cells. TAP-deficient counterparts TAP1-/- BMDC and TAP2-/-
RMA-S cells were included in the experiment, and the CD8+ T lymphocyte activation was 
measured. The efficiency of TAP-independent routes in both models was calculated by 
dividing the CD8+ activation after the stimulation with infected TAP-deficient cells by the 
activation after the stimulation with infected TAP-proficient cells. The results show a greater 
use of TAP-independent routes in BMDC than in the lymphoma cell lines (Figure 15). 
 
CD8
+
 T lymphocytes from VACV WR-infected C57BL/6 mice were purified 6 d.p.i. and stimulated in 
culture either with VACV WR-infected TAP1-proficient or TAP1-deficient BMDC, or VACV WR-infected 
TAP2-proficient (RMA) or TAP2-deficient (RMA-S) lymphoma cells. IFNγ production by CD8
+
 T 
lymphocytes was measured by flow cytometry and the percentage of activation values against TAP-
deficient/TAP-proficient cells was calculated separately for BMDC and for the lymphoma cell lines 
following the formula: (T-lymphocyte activation against TAP-deficient cells/T-lymphocyte activation 
against TAP-proficient cells)x100. Mean values and SEM of 2 to 4 effector:target ratios are shown.  
5.2. Proteolytic enzymes involved in TAP-independent antigen 
processing. 
5.2.1. Contribution of proteasomes to the generation of TAP-dependent and TAP-
independent epitopes. 
 Proteasomes are known to be the proteases with major proteolytic activity in the cell 
(Kloetzel and Ossendorp, 2004; Shastri et al., 2005) and, working together with other 
proteases in the cell, they generate many epitope precursors (Lázaro et al., 2015). For years, 
it has been believed that TAP-ind epitopes do not require proteasomal function since it is 
assumed that TAP-ind epitopes are not generated in the cytosol, and that they bypass TAP 
transport by the parental proteins using the Sec61 translocon or by other unknown 
Figure 15. TAP-independent routes are proportionally less efficient in the TAP2-/-
lymphoma cell line RMA-S than in TAP1-/- BMDC. 
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mechanisms. In fact, many engineered proteins provide TAP-ind epitopes in this way, not 
requiring any cytosolic machinery(Medina et al., 2009; Kim et al., 2011; Elliott et al., 1995; 
Snyder et al., 1994; Bacik et al., 1994; Raafat et al., 2011). However, in the last years, it has 
been known that proteasomes are involved in TAP-ind antigen processing (Oliveira et al., 
2014). With the aim of characterizing and quantifying the role of proteasomes in alternative 
TAP-ind antigen processing pathways acting on natural VACV proteins, we performed ICS 
assays with CD8+ T lymphocytes purified from spleens extracted from C57BL/6 VACV-
infected mice. We stimulated the effector cells with VACV-infected C57BL/6 or TAP1-/-BMDC 
treated or not with the proteasome inhibitor lactacystin (LC) and measured the CD8+ 
response (Figure 16). The results show that in both C57BL/6 and TAP1-/- infected BMDC the 
treatment with LC impairs viral antigen presentation. 
 
Figure 16. The proteasome inhibitor lactacystin partially impairs antigen presentation 
in both C57BL/6 and TAP1-/- BMDC. 
57 
 
Purified CD8
+
 T lymphocytes from spleens extracted from VACV WR-infected C57BL/6 mice five days 
post-infection were stimulated for 6 hours with VACV WR-infected C57BL/6 (A) or TAP1
-/-
 (B) BMDC 
treated or not with LC 10 μM during infection. In all cases CD8
+
 T lymphocytes were also stimulated in 
parallel with VACV WR-infected BMDC harboring a negative control haplotype (H-2
d
). One 
representative experiment out of four is shown. Relative contribution to CD8
+
 T-lymphocyte activation 
of alternative antigen processing pathways (TAP-independent and TAP-independent/LC-resistant) was 
calculated in non-saturating effector:target ratios using data from four experiments. Mean values and 
SD are shown (C). 
 To compare the role of proteasomes in both global (TAP-dependent and TAP-
independent together) and TAP-independent antigen presentation alone, we quantified the 
results from Figure 16A and Figure 16B by dividing the CD8+ T lymphocyte activation after 
LC-treatment by the activation against non-treated VACV-infected cells in both C57BL/6 and 
TAP1-/-cells (Figure 17). In both genotypes, the percentage of remaining activation after 
inhibition of proteasomal activity is similar. Regardless of the possible incomplete inhibition of 
the proteasomes by the LC treatment (Garcia-Medel et al., 2011), this would confirm that 
proteasomes play a very similar role in TAP-independent and TAP-dependent antigen 
presentation.  
 
Figure 17. Proteasomes contribute to antigen processing to the same extent in VACV 
WR-infected C57BL/6 and TAP1-/- BMDC. 
Purified CD8
+
 T lymphocytes from spleens extracted from VACV WR-infected C57BL/6 mice five days 
post-infection were stimulated for 6 hours with VACV WR-infected C57BL/6 or TAP1
-/-
BMDC treated or 
not with LC 10 μM during infection. The percentage of remaining antigen presentation in four 
experiments after LC treatment was calculated following the formula: (T-lymphocyte activation against 
LC-treated VACV WR-BMDC / T-lymphocyte activation against non-treated VACV WR-BMDC) x100for 
both C57BL/6 and TAP1
-/-
 VACV WR-infected BMDC. Mean values and SEM of four independent 
experiments are represented. 
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 Similar experiments with RMA and RMA-S cells were not performed due to the low 
level of TAP-independent antigen presentation. 
5.2.2. Identification of TAP-independent and lactacystin-resistant viral antigen 
presentation routes by using viral antigen-specific CTL lines. 
The ex vivo experiments showed CD8+ activation after the stimulation with LC-treated 
VACV-infected TAP1-/- BMDC (Figure 16B). We wondered whether that occurred because 
LC did not completely block proteasomal function and therefore we might be detecting 
antigens generated by residual proteasomes or, on the other hand, there were indeed TAP-
ind antigens that did not require proteasomal cleavage. To address these two possibilities, 
we studied the effect of LC on the generation of individual epitopes, rather than studying the 
collective presentation of all epitopes generated during a VACV infection. Previous results in 
our lab indicated that there were individual epitopes that resisted the treatment with LC, but 
all of them needed TAP to be presented (see Table 5later on) and therefore, they could not 
be responsible for the remaining presentation after LC treatment of infected TAP1-/- BMDC. 
For some VACV TAP-independent epitopes, the effect of LC had not been studied, because 
they were derived from post-replicative expression viral genes. Indeed, the treatment with 
proteasome inhibitors has the side effect that it impairs viral DNA replication, not allowing 
post-replicative viral proteins to be synthetized (Satheshkumar et al., 2009) (Figure 18A). 
This added difficulty to our work that needed to be bypassed, so we designed a different 
approach to the antigen presentation assay by adding the proteasome inhibitor LC at 
different times post-infection. This allows the antigenic proteins to be synthetized first, which 
let us check the effect of LC treatment on the generation of the epitope rather than on the 
replication of viral DNA (Figure 18B). 
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Figure 18. Diagram showing the side effect of proteasome inhibitors on VACV-infected 
cells. 
LC treatment impairs viral DNA replication and therefore, expression of post-replicative genes and 
protein products and epitopes (A). Allowing the infected cell to synthesize viral proteins and adding the 
proteasome inhibitor LC at later times post infection would allow to solely assess the effect of the 
inhibition on the generation of the epitopes (B). 
We generated CTL lines specific for TAP-ind antigens expressed by post-replicative 
expression genes. To generate CTL lines, we infected with VACV C57BL/6 mice, harvested 
their spleens and stimulated the splenocytes with the synthetic peptide of interest. With a 
total of six CTL lines we tested the involvement of proteasomes in antigen processing of 
each individual epitope. To this end, we performed CD8+ T lymphocyte activation assays with 
VACV-infected C57BL/6 BMDC adding LC at different times during the infection. We also 
tested at different times after infection to make sure we could detect each antigen in non-
saturating conditions. Since we did not have a quantifiable manner to classify the six 
epitopes as LC-enhanced (LCE), LC-resistant (LCR) or LC-sensitive (LCS), we generated 
other two CTL lines specific for two epitopes derived from early expression genes, B8R 
which is known to be LCS, and B2R, known to be LCE (Silvia Lázaro, personal 
communication). The addition of LC at different times post-infection blocked the presentation 
of B8R, but not the presentation of B2R, reproducing the previously known result (B8R as 
LCS and B2R as LCE) (Figure 19).Then we compared the presentation kinetics, after adding 
the proteasome inhibitor LC, of the 6 epitopes derived from post-replicative viral genes with 
the kinetics of the model epitopes B8R and B2R. We established that three of the six 
epitopes resisted to different extents the LC treatment (A19L, A25L and A6L), and the other 
three were LCS (A3L, A42R and E7R) (Figure 20). Since protein synthesis strongly 
correlates with antigen presentation (Croft et al., 2013), we can assume that the antigen 
presentation kinetics is a bona fide insight of protein synthesis, showing that there is some 
leakiness in post-replicative protein synthesis inhibition by LC treatment, as we detected 
some antigen presentation after treating infected cells with LC from the beginning of the 
infection (Figure 20).  
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C57BL/6 BMDC were infected with VACV WR for 0, 2 or 4 hours at 37ºC and the proteasome inhibitor 
LC was added at the beginning of the infection (●), 2 hours after the infection (■) or not at all (▲). 
These cells were used to stimulate CTL lines specific for the epitopes B8R and B2R and IFNγ 
production was measured by flow cytometry. Antigen presentation sensitivity to the inhibitor LC was 
assessed by comparing IFNγ production of CTL lines stimulated with BMDC infected for the same time 
but treated with LC for different hours. At all points, IFNγ production was relativized within the same 
experiment to  IFNγ production of CD8
+
 T lymphocytes stimulated with BMDC infected for the longest 
Figure 19. Antigen presentation kinetics after adding LC reproduces known sensitivity 
to the inhibitor for the model epitopes B8R and B2R. 
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time post-infection and not treated with LC.
 
Figure 20. Adding LC at different times post-infection allows assessing the 
requirement for proteasomes for the generation of epitopes derived from post-
replicative expression genes. 
C57BL/6 BMDC were infected with VACV WR for 0, 2, 4 or 6 hours and were used to stimulate CTL 
lines specific for the TAP-independent and post-replicative epitopes A19L, A25L, A6L, A3L, A42R and 
E7R. The proteasome inhibitor LC was added at the beginning of the infection (●), 2 hours later (■), 4 
hours later (▲) or not at all (▼). At all points, IFNγ production was relativized within the same 
experiment to IFNγ production of CD8
+
 T lymphocytes stimulated with BMDC infected for the longest 
time post-infection and not treated with LC. One representative experiment out of 3 or 5 for each CTL 
line is shown. 
 Besides, as a side result, we could compare the antigen presentation kinetics of all 
six epitopes included in the experiment by taking together the data corresponding to non-
treated cells (Figure 21). In this representation, we can observe that the presentation of A3L 
is earlier than the rest of the epitopes derived from late expression genes, which agrees with 
other evidence indicating that A3L is expressed in the early phase (personal 
communication).As antigen presentation more or less reflects source protein synthesis (Croft 
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et al., 2013), we can interpret these results as an indicator of the temporal gene expression 
of these viral proteins. In fact, the epitope A42R showed a presentation kinetic similar to A3L, 
suggesting that the epitope A42R could be derived from an early gene as well (Figure 
21).This proposed reclassification of the kinetic phase of expression for these two genes 
does not contradict the conclusions on sensitivity to LC, but simplifies their interpretation. In 
addition, these results are consistent with previous results obtained in our group on LC and 
A3L (Silvia Lázaro, personal communication). 
C57BL/6 BMDC were infected for 0, 2, 4 or 6 
hours with VACV WR and used to stimulate 
CTL lines specific for the TAP-independent 
epitopes A3L, A42R, A6L, E7R, A19L and 
A25L. IFNγ production was measured by flow 
cytometry and the relative CD8
+
 T-lymphocyte 
activation was calculated for each epitope 
separately according to the formula: (activation 
at “t” h.p.i. /activation at 6 h.p.i.) x100. The data 
show the mean and SEM of two or three 
experiments for each CTL line. 
 
 
Epitope 
TAP 
requirement 
Temporal expression 
Proteasome inhibitors 
sensitivity 
C57BL/6 
BMDCxVACV 
TAP1-/- 
BMDCxVACV 
A19L (47-55) ind Post-replicative LC
R - 
A23R (297-305) ind Early LCS - 
A25L (257-264) ind Post-replicative LC
R - 
A38L (203-210) ind Post-replicative - - 
A3L (270-277) dep Post-replicative LC
S - 
A42R (88-96) dep Post-replicative LC
S - 
A47L (138-146) dep Early LCS - 
A51R (78-85) dep Early LCR - 
Figure 21. TAP-independent epitopes 
derived from post-replicative expressed 
genes show great differences in the 
epitope presentation kinetics. 
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A6L (265-272) ind Post-replicative LC
R - 
A8R (189-196) ind Early LCS LCS 
A8R (70-77) dep Early LCS - 
B16R (275- 283) dep Post-replicative - - 
B1R (92-99) dep Early LCS - 
B2R (54-62) dep Early LCE - 
B6R (108-116) dep Early LCS - 
B8R (20-27) dep Early LCS - 
C4L (125-132) dep Early LCS - 
D1R (282-290) dep Early - - 
D1R (578-586) dep Early LCR - 
E7R (130-137) dep Post-replicative LC
S - 
E8R (141-150) ind Post-replicative - - 
F13L (307-315) ind Post-replicative - - 
F1L (200-207) dep Early LCS - 
F5L (279-287) ind Early - EpoS 
G8R (34-41) ind Post-replicative - - 
J3R (289-296) ind Early - LCS 
J6R (993-1000) dep Early LCS - 
K3L (6-15) dep Early LCS - 
L2R (53-61) ind Early LCS LCS 
L2R (61-69) dep Early - - 
Table 5. VACV MHC-I restricted epitopes included in this study. 
The 30 MHC-I restricted epitopes recognized by CD8
+
 T lymphocytes that were previously studied in 
our lab (Silvia Lázaro et al., in preparation) and their characteristics regarding their need for TAP(dep, 
dependent; ind, independent), the temporal expression of the genes that encode them and the 
sensitivity of their presentation after the addition of LC (LC
S
, sensitive; LC
R
, resistant; LC
E
, enhanced) 
and Epoxomicin (Epo) are summarized. Dashes (-) indicate not tested. Results obtained in this work 
are marked in bold. 
To compare the role of proteasomes in both global (TAP-dependent and TAP-
independent together) and TAP-independent antigen presentation alone, we compiled in 
Table 5 all the data in the lab (Silvia Lázaro et al., in preparation) and data from Figure 20 
and classified the epitopes whose presentation was sensitive (LCS), resistant (LCR) or 
enhanced by the treatment with LC (LCE) (Figure 22). From the 18 TAP-dep epitopes, while 
12 epitopes showed sensitivity to the treatment with LC, 2 epitopes resisted the treatment 
and the presentation of one epitope was enhanced by this inhibitor. These 3 epitopes that do 
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not show sensitivity to LC may account for at least part of the TAP-dependent viral antigen 
processing resistance to LC in Figure 16A. On the other hand, we detected TAP-ind viral 
antigen presentation resistant to LC in Figure 16B while we failed in finding individual 
epitopes resistant to LC in TAP1-/- BMDC. This can be due to an incomplete inhibition of 
proteasomal activity in Figure 16B or to the limited number of epitopes tested until now in 
TAP1-/- BMDC (4 out of 12). Three potential TAP-ind and LCR epitopes are A19L, A25L and 
A6L, which showed resistance to LC in C57BL/6 BMDC and are presented in TAP1 -/- BMDC 
(Table 5). However, most of the epitopes tested showed sensitivity to LC, which strongly 
agrees with the results obtained in ex vivo experiments (Figure 16A and B). 
Figure 22. Role of proteasomes in the 
processing of TAP-dep and TAP-ind 
VACV antigens. 
The number of epitopes according to their 
requirement for proteasomal processing is 
shown (numbers in bars). The percentage of 
epitopes within each group (TAP-dep, TAP-
ind and Total) is represented on the vertical 
axis. 
5.2.3. Role of non-proteasomal proteolytic enzymes in the processing of VACV 
antigens. 
 Knowing that proteasomes play the major role in TAP-independent antigen 
presentation and that there are also epitopes that are generated in the presence of a 
proteasome inhibitor in TAP-proficient cells, we aimed to know what protease or proteases 
participate in this kind of alternative antigen presentation pathways. 
 We chose a battery of protease inhibitors with different specificities (Table 6). None of 
these inhibitors showed a negative effect on the expression of GFP in BMDC infected with a 
VACV expressing GFP (Figure 23). 
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Inhibitor Abbreviation Specificity 
Concentration 
of use 
Reference 
Lactacystin LC Proteasomes 10 μM 
(Fenteany 
et al., 1995) 
Captopril - 
Angiotensin-converting 
enzyme 
150 μM 
(Looker et 
al., 2015b) 
Decanoyl-Arg-Val-Lys-
Arg-
chloromethylketone 
dec-RVKR-
cmk 
Proprotein convertases 50 μM 
(Garten et 
al., 1994) 
Leucinthiol LeuSH Metalloaminopeptidases 30 μM 
(Schumach
er and 
Schreiber, 
2015) 
N-Benzyloxycarbonyl-
Val-Ala-Asp-
fluoromethylketone 
z-VAD-fmk Caspases 100 μM 
(Zhu et al., 
1995) 
Table 6. Characteristics of the inhibitors of proteolytic activity used in this study. 
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Figure 23. The protease inhibitors lactacystin, captopril, dec-RVKR-cmk, leucinthiol 
and z-VAD-fmk do not impair VACV gene expression after infection of BMDC. 
BMDC were infected with rVV-GFP and treated or not with lactacystin (A), captopril (B), dec-RVKR-
cmk (C), leucinthiol (D) or z-VAD-fmk (E) during the infection. To assess the possible toxicity of the 
inhibitor during a VACV infection, GFP expression was measured by flow cytometry after one hour 
adsorption at 4ºC with (filled histogram) or without (continuous line, empty histogram) inhibitor (0 h.p.i.) 
and after one hour at 4ºC and four more hours at 37ºC with (dashed line) or without (dotted line) 
inhibitor (4 h.p.i.). In all cases, GFP mean fluorescence intensity was calculated and graphed (F). 
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 We then established specific CTL lines for TAP-independent epitopes and performed 
ICS assays stimulating them with VACV-infected BMDC treated or not with each protease 
inhibitor. Then, we calculated the percentage of inhibition of antigen presentation. The results 
showed that only the proprotein convertases inhibitor dec-RVKR-cmk and the 
metalloaminopeptidases inhibitor LeuSH had an effect on the presentation of some epitopes 
included in the experiments (Figure 24A). 
 
 
Figure 24. Inhibition of antigen presentation by protease inhibitors LeuSH, dec-RVKR-
cmk, z-VAD-fmk and Captopril. 
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C57BL/6 and TAP1
-/-
 BMDC were infected by a recombinant VACV encoding cytosolic OVA and 
treated or not with the protease inhibitors LeuSH, dec-RVKR-cmk, z-VAD-fmk and Captopril together 
or separately as indicated (A). After 6 hours of infection, BMDC were cocultured with epitope-specific 
CTL specific lines and CD8
+
 T-lymphocyte activation was measured by flow cytometry as an indicator 
of antigen presentation by MHC-I by infected cells. We included OVA as well as other VACV epitopes. 
Besides, we checked that the treatment with every inhibitor did not reduce the presentation of limiting 
amounts of each synthetic peptides (data not shown). For a better comprehension, data corresponding 
only to the treatment with dec-RVKR-cmk (B) and LeuSH (C) are graphed separately (B). Percentage 
inhibition of antigen presentation was calculated for each epitope and treatment, following the formula: 
(1-(activation against treated cells/activation against non-treated cells)) x100. Mean and SEM of 1 to 7 
independent experiments are shown. The dashed line marks 50% inhibition as an arbitrary indicator of 
relevant inhibition.  
For better comprehension, we graphed the results corresponding only to the BMDC 
treated with dec-RVKR-cmk (Figure 24B) or LeuSH (Figure 24C). We considered a relevant 
inhibition only if it exceeded 50% and with that criterion, the only epitope affected by dec-
RVKR-cmk treatment in VACV-infected C57BL/6 BMDC was the TAP-independent epitope 
A25L. Although with only one experiment, when the CTL are stimulated with infected TAP1-/- 
BMDC the only epitope inhibited by dec-RVKR-cmk is also A25L,, suggesting that proprotein 
convertases might participate in the TAP-independent antigen presentation pathway of this 
epitope. The fact that we are able to detect inhibition in C57BL/6 infected BMDC suggests 
either (1) that proprotein convertases not only might participate in the TAP-independent 
route, but also in the TAP-dependent pathway of this epitope, or (2), if they would only 
participate in the TAP-independent route, this route may have a major participation in the 
generation of this epitope, even in the presence of TAP. Results corresponding to non-
treated BMDC in Figure 24using CTL lines specific for A25L (not shown) indicated that, for 
this particular epitope, TAP-independent pathways would contribute around 19% to the total 
presentation of the epitope. These data would support the first hypothesis to explain the 
antigen presentation inhibition by dec-RVKR-cmk in infected C57BL/6 BMDC. 
Also, the inhibition shown after treatment with LeuSH suggests that aminopeptidases, 
presumably ERAP1 and/or ERAP2, might have a relevant role in antigen processing in the 
absence of TAP, since 2 out of 4 epitopes tested exceed the threshold of 50 % inhibition 
(Figure 24C). If that were the case, TAP-ind antigens would access the ER somehow during 
their processing. 
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5.3. Physiological relevance of TAP-independent antigen presentation 
pathways. 
5.3.1. Viral clearance kinetics in TAP1-/- mice.  
Once we described the role of proteasomes in TAP-independent antigen presentation 
and observed resistance to LC in TAP-proficient infected cells for some epitopes, we 
wondered if this kind of alternative pathways were relevant for viral clearance in vivo. With 
that purpose, we first studied the viral clearance kinetics in C57BL/6 and TAP1-/- mice. In 
particular, we measured the viral load in ovaries (Figure 25A) and spleens (Figure 25B) at 
different days after a sublethal VACV infection. The results show that initial viral replication 
was indistinguishable between TAP1-/- and C57BL/6 mice. Also, TAP1-/- mice cleared the 
infection in both organs as efficiently as C57BL/6 mice (Figure 25). 
 
Figure 25. TAP1-/- mice clear VACV in vivo as efficiently as C57BL/6 mice. 
C57BL/6 and TAP1
-/-
 mice were infected with 5·10
6
PFU of VACV WR and viral titers were measured 
at different days post-infection. Each point represents either the mean titer of two ovaries of the same 
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mouse (A) or the viral titer of the whole spleen (B). Three to eleven mice per group were used. Short 
lines indicate the median viral load of each group. The long black line indicates the detection limit of 
the viral titration assay.  
5.3.2. Involvement of CD8+ T lymphocytes in TAP-independent viral clearance. 
Knowing that VACV infection follows the same kinetics in both C57BL/6 and TAP1-/- mice, we 
wanted to know whether TAP-independent antigen presentation routes participate in the 
elimination of VACV-infected cells mediated by CD8+ T lymphocytes. With that purpose, we 
chose three TAP-ind epitopes to perform TAP-ind vaccination experiments (Table 7). 
 
Epitope 
TAP 
requirement 
Requirement for proteasomal 
activity 
Other proteases 
involved 
C57BL/6 
BMDCxVACV 
TAP1-/- 
BMDCxVACV 
J3R Ind* - Yes* n.d. 
A19L Ind* No - n.d. 
A25L Ind* No - Proprotein convertases 
B8R Dep* Yes* - n.d. 
Table 7. Characteristics of the epitopes regarding alternative antigen processing 
pathways included in in vivo experiments. 
The four epitopes included in further experiments are summarized in this table as well as the 
requirement for TAP, proteasomes and other known proteases. (*) Silvia Lázaro et al., in preparation. 
 We inoculated C57BL/6 and TAP1-/- mice intraperitoneally with TAP1-/- BMDC loaded 
with one of the synthetic peptides B8R, J3R, A19L or A25L. We included the epitopes J3R 
and B8R in the experiments due to their immunodominant role in the anti-VACV CD8+ 
lymphocyte response of TAP1-/- (J3R) and C57BL/6 mice (B8R). Fourteen days later, we 
infected the mice with 5·106 PFU of VACV and the viral clearance after the infection was 
tracked until the viral load in the ovaries was under the limit of detection. As we wanted to 
achieve a substantial viral load, we infected with a moderately high dose of virus, since it is 
known that higher doses lead to higher viral loads (Lin et al., 2013).The results show some 
improvement of viral clearance by CD8+ T lymphocytes in C57BL/6 mice vaccinated with the 
peptides J3R or A19L, as well as the immunodominant epitope B8R. However, TAP1-/-mice 
are not protected by these peptides (Figure 26). 
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Figure 26. Vaccination with J3R and A19L but not with A25L improves virus clearance 
from ovaries in C57BL/6 mice but not in TAP1-/- mice. 
C57BL/6 (A) and TAP1
-/-
 (B) mice were inoculated i.p. with LPS-matured BMDC previously incubated 
with the indicated synthetic peptides or with PBS alone as a negative control. Fourteen days later, 
mice were infected i.p. with 5·10
6
PFU of VACV WR. Viral load in the ovaries was measured 4, 7, 14 
and 21 days after the infection. The mean load of two ovaries of each mouse was calculated and 
graphed as an individual spot for each mouse. Short lines indicate the median viral load of each 
group. The long black line indicates the detection limit of the viral titration assay. Mann-Whitney U 
tests to compare difference of medians of viral load taking as a control PBS-incubated mBMDC were 
performed for each day post-infection (p value ≤ 0.001, ***; p value ≤ 0.005, **; p value ≤ 0.05, *). 
 We performed the same experiment tracking the viral load in the spleens. These 
results showed an improved capacity of CD8+ T lymphocytes to clear the infection after 
vaccination with J3R, A19L or A25L synthetic peptides in TAP1-/- mice, while only the 
vaccination with the epitopes J3R and A19L showed significant protection in C57BL/6 mice 
(Figure 27). The fact that the inoculation consisted in synthetic peptides that are recognized 
by CD8+ T lymphocytes proves that this improved clearance after vaccination is due to the 
sole action of these cells.  
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Figure 27. The TAP-independent epitopes J3R and A19L confer protection against a 
VACV infection in vivo in both C57BL/6 and TAP1-/- mice. 
C57BL/6 (A) and TAP1
-/-
 (B) mice were inoculated with LPS-matured BMDC loaded with the indicated 
synthetic antigenic peptides. Fourteen days later, mice were infected with 5·10
6
PFU of VACV WR and 
three days after infection, spleens were extracted to measure the viral titer. The black line indicates 
the detection limit of the viral titer assay. Data from four independent experiments with a total of at 
least seven mice per group is shown. Mann-Whitney U tests to compare difference of medians of viral 
load taking as a control PBS-incubated mBMDC were performed (p value ≤ 0.001, ***; p value ≤ 0.01, 
**; p value ≤ 0.05, *). 
However, we also performed ICS assays after challenge infection to check the cell 
response itself. With the exception of A19L and A25L in TAP1-/- mice, all the inoculations led 
to an increased CD8+ response against the inoculated peptide, compared to mice that were 
inoculated only with mature BMDC (mBMDC). We also detected a higher background 
response to most peptides in TAP1-/- mice (Figure 28). We detected a lesser percentage of 
CD8+ T lymphocytes in TAP1-/- mice compared to C57BL/6 mice  in both PEC and spleens 
(3.8 % ± 2.2 % CD8+ lymphocytes in TAP1-/-versus 14.2 % ± 5.1 % in C57BL/6 PEC and 1.8 
% ± 0.7 % in TAP1-/-versus17.1 % ± 5.3 % in C57BL/6 spleens).This agrees with previously 
described similar data in uninfected mice (van Kaer et al., 1992). 
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Figure 28. Immunization with mBMDC loaded with antigenic peptides leads to an 
enhanced CD8+ T lymphocyte response after viral infection. 
C57BL/6 (A) or TAP1
-/-
 (B) mice were immunized with mBMDC loaded either with PBS or with J3R, 
A25L or A19L antigenic peptides. Fourteen days later mice were challenged with 5·10
6
PFU of VACV 
and three days after infection the CD8
+
 T lymphocyte response from PEC against each peptide (B8R, 
white; J3R, black; A19L, dark grey; A25L, light grey) was measured in an ICS assay. 
The effective viral clearance by CD8+ T lymphocytes after vaccination in spleens but 
not in ovaries in the absence of TAP shows that alternative antigen processing pathways 
have differential physiological relevance to clear a VACV infection depending on other 
factors in addition to the presence of TAP. To clarify this question, we hypothesized that 
MHC-I density may underlie the differences in protection between ovaries and spleens. H-
2Kb binds and presents to CD8+ T lymphocytes the peptides summarized in Table 7. 
Therefore, we measured by flow cytometry the H-2Kbsurface expression in C57BL/6 and 
TAP1-/- ovaries and spleens (Figure 29). The results showed a negative correlation between 
MHC-I expression and viral load in C57BL/6 mice, being the spleen the organ with more 
MHC-I and less viral load at early days post-infection. This is consistent with higher MHC-I 
levels contributing to better CD8+ T lymphocyte-mediated control of virus. However, this 
cannot be concluded about TAP1-/- mice, since both ovaries and spleens show a similar 
MHC-I expression, despite very different viral titers (Figure 29B).The lower MHC-I surface 
expression in TAP1-/- mice was already described(van Kaer et al., 1992). Therefore, MHC-I 
expression alone does not explain the differences observed in the results regarding 
protection against VACV. 
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Figure 29. At early days post-infection ovaries have more virus than spleens which 
correlates with a lower MHC-I surface expression in C57BL/6 mice, but not in TAP1-/- 
mice. 
C57BL/6 and TAP1
-/-
 mice were infected with VACV WR and viral load was measured at day 3 (for 
spleens) or day 4 (for ovaries) post-infection. Dots represent individual mice, corresponding to the 
same data from previous experiments (A). Spleens and ovaries were extracted from uninfected 
C57BL/6 and TAP1
-/-
 mice and surface H-2K
b
 expression was measured. Fluorescence from cells 
incubated with isotype control was subtracted to obtain the specific MFI and data was relativized within 
the same experiment to cells with the highest MFI signal (C57BL/6 splenocytes). Data from 3 
independent experiments is shown (B). Medians of each group are shown by black lines in A, while 
means and SEM are shown in B. 
5.4. Differential features of VACV TAP-independent epitopes. 
5.4.1. Hydrophobicity of VACV immunogenic epitopes as a potential driver of TAP 
independence. 
After studying the antigen presentation mechanisms and the relevance of TAP-
independent routes, we wondered which features conferred a peptide the capability of being 
processed and presented in a TAP-independent manner. A previous work that studied the 
TAP requirement of nine epitopes derived from the Epstein Barr virus (EBV) LMP2 protein 
identified a correlation between the hydrophobicity of the epitopes and their requirement for 
TAP to be presented by HLA molecules, being the TAP-independent epitopes the most 
hydrophobic (Lautscham et al., 2003) (Table 8). We calculated the hydrophobicity score 
using the optimal matching hydrophobicities calculation (OHM) which is a value used to 
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predict conformational similarities of proteins from their aa sequences. Numerical values for 
hydrophobicity, OHMs, are assigned to each aa residue to allow comparisons based upon 
features of the residues that are important for their structural function, but independent of 
actual aa identities(Sweet and Eisenberg, 1983). 
Epitope 
HLA 
restriction 
Hydrophobicity 
(OHM score) 
Relative 
hydrophobicity* 
TAP 
requirement 
Epitope 
location 
LLWTLVVLL A*0201 8,14 0,90 ind TM 
FLYALALLL A*0201 7,64 0,84 ind TM 
WTLVVLLI B*63 6,95 0,87 ind TM 
PYLFWLAAI A*23 6,49 0,72 ind TM 
TYGPVFMCL A*2402 5,47 0,61 ind 
4 aa 
Cytosol + 
5 aa TM 
CLGGLLTMV A*0201 4,14 0,46 ind TM 
IEDPPFNSL B*4001 -0,59 -0,07 dep Lumen 
RRRWRRLTV B*2704 -0,60 -0,07 dep Cytosol 
SSCSSCPLSK A*1101 -2,35 -0,24 dep Cytosol 
Table 8. Epitopes from the EBV protein LMP2 included in Lautscham et al., 2003. 
The epitopes studied in Lautscham et al, 2003 are summarized and their hydrophobicity and TAP 
status are shown (dep, dependent; ind, independent).TAP-ind epitopes are colored in grey. *Relative 
hydrophobicity is calculated by dividing the OHM hydrophobicity score by the number of aa in the 
peptide sequence. TM: transmembrane, aa: aminoacid. 
Besides, the six TAP-independent epitopes were part of transmembrane (TM) 
regions. The fact that the eight epitopes derive from the same protein, suggest that the 
requirement for TAP is driven by a feature of the peptide or a precursor rather than a feature 
of the protein (LMP2). Also, the observation that the TAP-independent epitopes are part of 
TM regions suggests a question: Is the high hydrophobicity a cause of their TAP-
independency or is it only a consequence of their TM location? 
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To answer that question, we would need a high variety of TAP-independent epitopes 
derived from different proteins and secondary structures. Previous results in our lab provide 
that tool, since 30 MHC-I restricted epitopes encoded by VACV were tested for their 
requirement of TAP (Silvia Lázaro, personal communication). Twelve out of thirty were 
presented in a TAP-independent manner and only five of them contained at least one aa in a 
TM region (                                     Table 9). 
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Epitope Sequence 
H-2 
restriction 
Hydrophobicity 
(OHM score) 
Relative 
hydrophobicity* 
TAP 
requirement 
Epitope 
location 
L2R (53-61) VIYIFTVRL K
b
 8,26 0,92 ind 9 aa TM 
A8R (189-196) ITYRFYLI K
b
 8,11 1,01 ind Cyt 
G8R (34-41) LMYIFAAL K
b
 7,50 0,94 ind 
5 TM aa + 
3 Cyt aa 
A23R (297-
305) 
IGMFNLTFI D
b
 6,71 0,75 ind Cyt 
A38L (203-
210) 
KVFSFWLL K
b
 6,47 0,81 ind 
6 TM aa  
+ 2 Cyt aa 
D1R (282-290) LGYIIRYPV D
b
 6,22 0,69 dep Cyt 
A8R (70-77) IHYLFRCV K
b
 5,91 0,74 dep Cyt 
B6R (108-116) LMYDIINSV K
b
 5,54 0,62 dep Cyt 
J3R (289-296) SIFRFLNI K
b
 5,50 0,69 ind Cyt 
J6R (993-
1000) 
INFEFVCL K
b
 5,25 0,66 dep Cyt 
A6L (265-272) YTLIYRQL K
b
 5,25 0,66 ind Cyt 
A25L (257-
264) 
SIYQYVRL K
b
 4,67 0,58 ind Luminal 
A3L (270-277) KSYNYMLL K
b
 4,66 0,58 dep Cyt 
E8R (141-150) FWFKNTQFDI D
b
 4,42 0,44 ind 
3 TM aa + 
7 Cyt aa 
B1R (92-99) INVEYRFL K
b
 4,24 0,53 dep Cyt 
A42R (88-96) YAPVSPIVI D
b
 4,06 0,45 dep Cyt 
A19L (47-55) VSLDYINTM K
b
 4,01 0,45 ind Cyt 
D1R (578-586) SMYCSKTFL D
b
 3,95 0,44 dep Cyt 
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B16R (275-
283) 
ISVANKIYM D
b
 3,56 0,40 dep Luminal 
L2R (61-69) LVSRNYQML K
b
 3,07 0,34 dep 2 TM aa 
A47L (138-
146) 
AAFEFINSL K
b
 2,82 0,31 dep Cyt 
C4L (125-132) LNFRFENV K
b
 2,32 0,29 dep Cyt 
B2R (54-62) YSQVNKRYI D
b
 1,86 0,21 dep Cyt 
K3L (6-15) YSLPNAGDVI D
b
 1,71 0,17 dep Cyt 
A51R (78-85) RISRFANL K
b
 1,34 0,17 dep Cyt 
B8R (20-27) TSYKFESV K
b
 1,23 0,15 dep Luminal 
F1L (200-207) STREYLKL K
b
 0,80 0,10 dep Cyt 
E7R (130-137) STLNFNNL K
b
 0,77 0,10 dep Cyt 
F13L (307-
315) 
FTIQNNTKL D
b
 0,41 0,05 ind Cyt 
F5L (279-287) SAPMNVDNL D
b
 -0,44 -0,05 ind 
1 TM aa + 
8 luminal 
aa 
                                     Table 9. MHC-I restricted epitopes included in Silvia Lázaro et al. 
The epitopes studied in our lab (Silvia Lázaro et al., in preparation) are summarized, tabulated according 
to their OHM score and their sequence, H-2 restriction, hydrophobicity score, TAP requirement(dep, 
dependent; ind, independent) and the location of the epitope within the protein is shown. TAP-ind 
epitopes are colored in grey. *Relative hydrophobicity is calculated by dividing the hydrophobicity score 
by the number of aa in the peptide sequence. TM: transmembrane; Cyt: Cytoplasmic; aa: aminoacid. 
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 To make sure that any possible difference in hydrophobicity was not mediated by the 
hydrophobicity of the protein that the epitopes are derived from, we calculated in the same 
way the OHM score for all 30 VACV proteins included in the analysis. To be able to compare 
the scores of the proteins and the epitopes, we represented the relative hydrophobicity (OHM 
score/number of residues of the protein or peptide). The results show that the VACV proteins 
that include TAP-ind or TAP-dep epitopes do not differ in their hydrophobicity score, while 
the epitopes do. In harmony with Lautscham et al., TAP-ind epitopes showed higher 
hydrophobicity score than TAP-dep epitopes (Figure 30). Filtering the epitopes by their H-2 
restriction, we observed that the difference in hydrophobicity between H-2Kb restricted TAP-
ind epitopes and H-2Kb restricted TAP-dep epitopes is more significant than if we include 
also the H-2Db restricted epitopes. 
 
Figure 30. TAP-independent epitopes are more hydrophobic than TAP-dependent 
epitopes, while the proteins they derive from show similar hydrophobicity scores. 
OHM hydrophobicity score was calculated for 30 immunogenic VACV-encoded peptides, precursors of 
these peptides (with 10 or 4 aa N-terminal extensions) and the proteins they derive from. H-2K
b
 
binding epitopes are depicted in black together with H-2D
b
 binding peptides, depicted in red (A). All 
twenty H-2K
b
 binding epitopes are graphed alone in B. Mean and SEM values for each group are 
shown. 
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5.4.2. Hydrophobicity of potential precursors of immunogenic VACV peptides. 
Knowing that TAP-independent VACV MHC-I restricted epitopes are more 
hydrophobic than TAP-dependent epitopes and that the proteins they come from do not differ 
in this feature, we wondered how far this significant difference would be observed if we 
calculated the OHM score for different extensions of the epitopes. This would give some 
hints about which is the molecule transported in the absence of TAP, whether a precursor 
peptide or the ligand itself, assuming that hydrophobicity is the feature or one of the features 
that provide peptides with the capability to be transported in a TAP-independent manner. We 
calculated the OHM score for sequences including the epitope and 0 to 20 aa extended in 
the N-terminus, C-terminus or both for all 12 TAP-independent epitopes and 18 TAP-
dependent epitopes. T-tests were performed to test the difference of means in hydrophobicity 
between TAP-ind and TAP-dep epitopes for each number of aa extended (Figure 31). 
 
Figure 31. Residues in the N-terminal extensions are differentially more hydrophobic 
in TAP-ind-processed epitopes than C-terminal residues. 
The OHM hydrophobicity score was calculated for the 20 VACV epitopes presented by the H-2K
b
 
haplotype previously studied and their potential precursors extended in N-terminus, C-terminus, or 
both. T-test analyses to compare the difference of means between TAP-ind and TAP-dep epitopes 
were performed. P values resulting from the tests for sequences including the epitope and each 
number of residues extended are shown (dotted line, p value=0.001; dashed line, p value=0.005; full 
line, p value=0.05). Extensions larger than shown resulted in less significant difference of 
hydrophobicity.  
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The results show that, while in C-terminal extended precursors the significant 
difference in hydrophobicity between TAP-ind and TAP-dep epitopes was rapidly lost, adding 
aa in the N-terminus preserved the differences for more than ten extended aa. That means 
that a precursor of a TAP-independent epitope extended up to ten aa in the N-terminus is 
very likely more hydrophobic than a similar precursor of a TAP-dependent epitope. Still 
assuming that hydrophobicity is indeed a relevant parameter in TAP-independent transport, 
these results would imply that the peptide itself or an N-terminally extended short precursor 
are the molecules transported to a MHC-I containing compartment in the absence of TAP. 
 Further, we calculated OHM scores for epitopes extended in different lengths at both 
the C- and N-termini. We studied if extensions at the C-terminus affect the differential 
hydrophobicity of N-terminally extended epitopes. The results show that extending aa at the 
C-terminus greatly affects the differential hydrophobicity of TAP-ind and TAP-dep peptides, 
and that N-terminally extended TAP-ind peptides are more distinguishable from N-terminally 
extended TAP-dep peptides when the extension is short (up to four residues) (Table 10). 
  
C-terminal extended aminoacids 
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0 0.0015 0.0100 0.0340 0.1179 
1 0.0120 0.0096 0.0344 0.1065 
2 0.0230 0.0166 0.0383 0.1311 
3 0.0008 0.0056 0.0146 0.0408 
4 0.0032 0.0178 0.0356 0.0736 
5 0.0085 0.3030 0.5030 0.1048 
6 0.0095 0.0299 0.0461 0.0922 
7 0.0191 0.0563 0.0861 0.1474 
8 0.0097 0.0295 0.0440 0.0800 
9 0.0156 0.0414 0.0598 0.1064 
10 0.0264 0.0639 0.0895 0.1440 
11 0.1057 0.1930 0.2537 0.3664 
12 0.2578 0.3863 0.4581 0.6129 
Table 10. The difference in hydrophobicity between TAP-ind and TAP-dep epitopes is 
more significant in short N-terminal-extended precursors. 
The OHM hydrophobicity score was calculated for the 20 immunogenic VACV epitopes presented by 
the H-2K
b
 haplotype previously studied and their extensions in C and N-termini. T-student tests were 
performed to compare the difference in hydrophobicity between TAP-ind and TAP-dep epitopes and 
their extensions. The p values for each test are summarized in the table. Non-significant p values are 
non-colored, p values<0.05 are colored in light grey, p values between 0.05 and 0.005 are colored in 
grey and p values<0.001 are colored in dark grey. 
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5.4.3. Amphipaticity of epitopes and N-terminal extended precursors. 
 Further, we wondered if another peptide feature could also be potentially a 
characteristic to distinguish TAP-ind from TAP-dep epitopes. Amphipaticity is the 
organization of polar and non-polar residues of a helical peptide at different sides of the helix. 
It is calculated assuming a perfect helical conformation, calculating the vectorial sum of the 
hydrophobic moment of each aa. We speculated that the higher the amphipaticity of a 
peptide is, the easier it might pass through membranes (and therefore, bypass TAP). We 
calculated the amphipaticity of all 18 TAP-dep epitopes and 12 TAP-ind epitopes known in 
VACV and their N-terminal extended precursors, as these precursors may be the molecule 
transported through membranes according to hydrophobicity analysis. The results show, 
unlike hydrophobicity, no difference between TAP-dep and TAP-ind peptides, neither 
between the epitopes, nor between short N-terminal extended precursors (Figure 32). 
Figure 32. Neither TAP-ind nor TAP-dep 
epitopes nor their N-terminal extended 
precursors differ in amphipaticity. 
Amphipaticity scores for 30 immunogenic VACV 
epitopes and their N-terminal extended 
precursors were calculated using the site 
“helical wheel projection” created by Don 
Armstrong and Raphael Zidovetzki: Version Id: 
wheel.pl,v 1.4 2009-10-20 21:23:36 don Exp. T-
tests to compare difference of means were 
performed and none resulted statistically 
significant. 
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6. DISCUSSION. 
6.1. Potential pathways for TAP-independent cross-presentation by 
BMDC. 
 To analyze the pathway or pathways involved in TAP-independent cross-presentation 
by BMDC we targeted the SNARE protein Sec22b, involved in the trafficking of vesicles from 
the ER to Golgi vesicles (Hay et al., 1997; Zhang et al., 1999) and to phagosomes (Becker et 
al., 2005). By fusing ER-derived vesicles to the Golgi apparatus, Sec22b allows the 
anterograde transport of proteins from the ER, including loaded MHC-I molecules (Figure 
33A). On the other hand, Sec22b allows the fusion of ER-derived vesicles to phagosomes, 
providing also the latter with components of the peptide loading complex (PLC) and making 
possible the load in phagosomes of MHC-I molecules with their ligands (Figure 33B). 
 The exact mechanism by which antigens are cross-presented in TAP-deficient BMDC 
is unknown. Knowing that TAP-independent cross-presentation of ovalbumin depends on 
proteasomal activity to take place in BMDC (Merzougui et al., 2011), we proposed three 
potential pathways for this kind of antigen presentation. First, the antigen would access the 
ER in a TAP-independent way and load onto nascent MHC-I molecules, following the 
canonical antigen presentation route from that point (Figure 33A). A second possibility is that 
the antigen would access phagosomes in a TAP-independent way, binding MHC-I molecules 
coming from the ER to the phagosomes via Sec22b (Figure 33B). In a third alternative, the 
antigen would access phagosomes in a TAP-independent way and it would bind MHC-I 
molecules coming from the recycling of surface MHC-I (Figure 33C). Since the two first 
hypotheses depend on the function of Sec22b, we decided to silence its expression and 
assess the remaining cross-presentation in TAP1-/-BMDC. Since the results showed that 
TAP-independent cross-presentation is completely independent of this protein (Figure 9), the 
third hypothesis gained more credibility. Also, the treatment with primaquine, which partially 
inhibits the recycling of MHC-I molecules (Reid and Watts, 1990; Houot et al., 2015) 
increases the MHC-I molecule amount in endosomes in TAP1-/- BMDC, correlating with an 
increased antigen cross-presentation by the same cells under primaquine treatment 
(Merzougui et al., 2011). This supports an important role of recycling endosomes in TAP-
independent cross-presentation, as our data suggest. Taking together that (1) the 
proteasome is required for TAP-independent cross-presentation, (2) Sec22b is dispensable 
for OVA cross-presentation by TAP1-/- BMDC and (3) recycling endosomes play an important 
role in TAP-independent cross-presentation; we propose that after phagocytosis, the antigen 
would access the cytosol to be processed by proteasomes. After that, the proteasomal 
products, as it has been already proposed (Merzougui et al., 2011), would access 
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phagosomes in a TAP-independent way where they would bind MHC-I molecules coming 
from recycling endosomes and finally, the MHC-I/peptide complex would be presented back 
on the plasma membrane (Figure 33C). 
 
Figure 33. Diagram showing the potential pathways for TAP-independent cross-
presentation. 
The diagram shows our three different hypotheses for TAP-ind antigen cross-presentation. In A, the 
processed antigen would access the ER through an unknown mechanism and would follow the 
canonical secretion pathway to be loaded onto MHC-I in a Sec22b-dependent process. In B, the 
processed antigen would access the phagosome from the cytosol by an unknown mechanism and 
would be loaded in the phagosome onto MHC-I molecules coming from the ER in a Sec22b-
dependent manner. In C, the processed antigen would access the phagosome from the cytosol by an 
unknown mechanism and would be loaded onto recycled MHC-I molecules from the plasma 
membrane in the phagosome. 
 On the other hand, cross-presentation of the same antigen by C57BL/6 BMDC does 
require the function of Sec22b to some extent (Cebrian et al., 2011) and we have reproduced 
these results. Most probably, the internalized exogenous antigen follows the canonical 
antigen presentation route after processing by proteasomes. In fact, the remaining antigen 
presentation after silencing Sec22b in C57BL/6 BMDC is very similar to that of TAP1-/- BMDC 
(Figure 9). This suggests the existence of at least two paths of cross-presentation of OVA-
beads by BMDC: one dependent on TAP and Sec22b, and other independent of both TAP 
and Sec22b (Figure 34). 
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Figure 34. Diagram showing the main hypothesis 
for TAP-dependent and TAP-independent 
antigen cross-presentation by BMDC. 
After internalization of the full length antigen to the 
dendritic cell and export to the cytosol from phagosomes 
for proteasomal cleavage, the processed antigen would 
access the phagosome either by TAP (blue) or bypassing 
this transporter (green). There, the antigen would load 
either onto MHC-I molecules coming from the ER via 
Sec22b (blue) or onto MHC-I molecules coming from the 
plasma membrane (green). 
 
 
 
6.2. Alternative routes of direct MHC-I viral antigen presentation. 
Alternative routes of direct MHC-I antigen presentation refer to all routes that bypass 
one or more of the key players in canonical direct presentation, such as (1) proteasomes, (2) 
TAP or (3) nascent MHC-I molecules. For some time, it was assumed that most TAP-
independent antigens were derived from proteins entering the ER through their signal 
sequence and therefore, besides not needing TAP, they would also not require proteasomal 
cleavage (reviewed in (Del Val et al., 2011)). However, several cases of antigens processed 
in a TAP-independent but proteasome-dependent way have been coming out (Lautscham et 
al., 2001; Merzougui et al., 2011; Oliveira et al., 2014), breaking the old barrier between 
canonical and non-canonical antigen processing pathways.  
6.2.1. Proteolytic enzymes involved in TAP-independent antigen presentation 
pathways. 
 Proteolytic enzymes catalyze the cleavage of peptide bonds, either in proteins or 
peptides. Their functions are varied, from maintaining the cellular homeostasis to producing a 
functional form of a protein. They also play a key role in antigen processing, making possible 
the cleavage and trimming of proteins and peptides, producing a huge amount of products 
differing in sequence as well as in length.  
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 While proteasomes have had a key role in antigen processing, the generation of 
MHC-I ligands is not limited to this protease, but there is an increasing number or proteases 
also involved in antigen processing (reviewed in (Lázaro et al., 2015)). They can trim 
proteasomal products (Stoltze et al., 2000; Saric et al., 2001; Towne et al., 2005; Towne et 
al., 2008; Zervoudi et al., 2013; Gonzalez-Villalobos et al., 2013) but they can also work 
independently of proteasomes (Gil-Torregrosa et al., 1998; Tomkinson, 1999; van Endert, 
2008; López et al., 2010; Parmentier et al., 2010; Oliveira et al., 2013). 
 One of the aims of this work was to assess the role of proteasomes and other 
proteases in TAP-independent MHC-I viral antigen presentation. While the background in 
TAP-ind antigen presentation assumed that TAP-independency meant independence of 
proteasome cleavage, it has been suggested that that observation may respond to a bias in 
the research of TAP-ind antigens (Del Val et al., 2013). The results we obtained show, on the 
other hand, that TAP-independency does not necessarily mean proteasome-independency, 
yet in agreement with other similar study (Oliveira et al., 2014). In fact, proteasomal cleavage 
is highly important in the generation of TAP-independent MHC-I VACV antigens (Figure 16B 
and C), even to the same extent as in global MHC-I VACV antigen presentation (Figure 
17).It is true that, as the transcription of post-replicative expression genes is inhibited by the 
proteasome inhibitor lactacystin (Satheshkumar et al., 2009), we could be overestimating the 
effect of lactacystin on VACV TAP-ind antigen presentation, but it is also known that around 
65% of the CD8+ T lymphocytes activated against VACV epitopes are specific for early 
expression genes (Moutaftsi et al., 2010).As proteasomes are the major and more 
multicatalytic cellular proteases, this would imply that both TAP-dep and TAP-ind pathways 
sample undistinguishable intracellular pools of peptides for proteolytic action. Interestingly, 
the fraction of antigenic VACV proteins located in cytosol (compared to those in vesicular 
compartments) is similar for TAP-dep and TAP-ind routes, as well as for LCR and LCS 
pathways (Lázaro S, PhD report).The remaining antigen presentation in TAP1-/- BMDC that 
we detected after LC treatment (33% of TAP-independent viral antigen presentation and 
6.6% of global viral antigen presentation) could be due either to an incomplete inhibition of 
proteasomal cleavage by the inhibitor LC or else to antigens generated in a TAP-
independent and LC-resistant way. Also, the inhibition of post-replicative viral genes 
replication by the treatment with LC could be underestimating the possible LCR TAP-dep and 
LCRTAP-ind viral antigen presentation. We generated specific CTL lines against TAP-
independent VACV epitopes to find out if some of them could actually be generated in the 
presence of LC. We found that three out of six epitopes tested were LC-resistant (A19L, A6L 
and A25L)in C57BL/6 BMDC (Figure 20). In addition, we could find an alternative proteolytic 
pathway for one of them (A25L).The generation of this epitope was highly impaired in the 
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presence of dec-RVKR-cmk, suggesting an important role of pro-protein convertases. 
(Figure 24). This family of proteases was already known to be involved in antigen 
presentation (Gil-Torregrosa et al., 1998; Gil-Torregrosa et al., 2000; Medina et al., 2009). 
However, the failure in finding alternative proteases for the generation of the epitopes A19L 
and A6L in the presence of LC shows that there are other proteases besides those included 
in this work that are responsible for their generation. 
 The global analysis of the epitopes studied in our lab (Table 5) shows a non-
preferential cleavage by proteasomes of TAP-dependent and TAP-independent epitopes, 
supporting the idea that proteasomal cleavage and TAP transport are not necessarily linked. 
In a scenario in which proteolytic enzymes and transport through membranes work 
separately in the generation of antigens, the possibilities in the generation of a given antigen 
are quite open. This would establish that there is not a sole alternative TAP-independent 
pathway, but many. 
 Overall, we must not forget that the techniques here used have a good but lower 
sensitivity to detect MHC-I/peptide complexes than mass spectrometry-based approaches 
(Purcell et al., 2016). This could underestimate to some extent the level of antigen 
presentation we are detecting in this work. 
6.3. Potential mechanisms and products for TAP-independent transport. 
 While we know increasingly more epitopes that are presented in a TAP-independent 
way (Gueguen et al., 1994; Gil-Torregrosa et al., 1998; Sigal and Rock, 2000; Lautscham et 
al., 2001; Oliveira et al., 2011),the mechanisms and routes that make possible the transport 
of peptides through membranes in a TAP-deficient scenario are largely unknown. None of 
the studies describing TAP-independent antigen presentation have succeeded in finding a 
defined pathway or mechanism that can transport those antigens through membranes other 
than TAP. Even more, we do not know what makes an antigen suitable for TAP-independent 
transport or which exact molecule is transported in a TAP-independent way. Here, we 
discuss the differential characteristics found in TAP-dependent and TAP-independent 
antigens and the possible and more likely protein products that are transported in the 
absence of TAP. 
6.3.1. Differential characteristics between TAP-independent and TAP-dependent 
antigens. 
 In the seek of a common characteristic in TAP-independent antigens that can also 
differentiate them from TAP-dependent peptides, only a few studies have succeeded in 
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finding one ((Lautscham et al., 2003) and Lázaro S. et al., in preparation). Many 
characteristics of the peptides and the proteins they derive from have been analyzed, such 
as temporal expression (in the case of viral proteins), protein function, protein localization, 
localization of the epitope within the protein, net charge of peptides and their precursors 
(Lázaro S.  et al, inpreparation) and hydrophobicity of proteins, precursors (Figure 30 and 
Figure 31) and peptides ((Lautscham et al., 2003) and Lázaro S. et al.); as well as 
amphipaticity of precursors and peptides (Figure 32). However, besides minor variations in 
MHC-I bindng motifs, only peptide and precursor hydrophobicity has been determined to be 
significantly different in TAP-independent peptides when compared with TAP-dependent 
peptides. Also, a higher prevalence of peptides derived from viral structural proteins for TAP-
independent epitopes than in their TAP-dependent counterparts was found (Lázaro S. et al, 
in preparation). 
 But, if higher hydrophobicity is indeed allowing peptides to be transported in the 
absence of TAP, which could be the mechanisms responsible? As reviewed(Del Val et al., 
2011), there are different mechanisms that could be capable of transporting a peptide or 
protein through membranes: 
1. Co-translational transport through Sec61 of membrane and secreted proteins. 
2. Transport to the ER by another transporter. 
3. Transport to endolysosomal compartments by another transporter. 
4. Transport to endolysosomal compartments by autophagy. 
5. Diffusion through membranes. 
6. Post-translational transport of small peptides, including cleaved signal sequences, by 
calmodulin (Shao and Hegde, 2011). 
7. Post-translational transport to the Sec61 translocon of tail-anchored and short 
secretory proteins by TRC40/WRB (Yamamoto and Sakisaka, 2012; Johnson et al., 
2012). 
Of all these potential mechanisms, hydrophobicity would only benefit transport by another 
transporter with high affinity for hydrophobic peptides and also could lead to passive diffusion 
through membranes (2, 3, 5, 6 and 7). However, although in this work we failed in silencing 
the expression of the peptide transporter TAPL to assess its possible role in MHC-I antigen 
presentation, other authors (Oliveira et al., 2014) could observe that silencing this gene did 
not affect at all the presentation of a TAP-independent self peptide. On the other hand, there 
are no studies relating passive diffusion through membranes and TAP-independence. 
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6.3.2. Determination of the length of protein products that are transported in the 
absence of TAP. 
 In order to find one or more TAP-independent antigen transport pathways we decided 
to focus on the potential substrates of transport. Once a protein is synthesized, an antigenic 
peptide derived from it could access a MHC-I-containing compartment by three different 
ways: (1) the protein itself accesses the compartment passing through the translocon (if it 
contains a signal sequence) or other post-translational translocation mechanism (if it doesn’t 
contain a signal sequence) and the peptide is generated in the vesicular pathway (Figure 
35A); (2) the protein, if cytosolic, is partially degraded in the cytosol and a precursor of the 
antigenic peptide is transported through membranes (Figure 35B) and(3) the cytosolic 
protein is partially degraded and the correct MHC-I ligand is transported through membranes 
to the vesicular pathway (Figure 35C). 
 
Figure 35. Potential substrates of transport to MHC-I-containing compartments in the 
absence of TAP. 
The diagram shows the three possible cytosolic substrates for the transport to the ER. In A, the whole 
protein is transported to the MHC-I-containing compartment, either mediated by a signal sequence or 
other mechanisms. In B, the protein is partially cleaved by cytosolic proteases and the ligand 
precursors are transported to the MHC-I-containing compartment. Finally, in C the cytosolic proteases 
cleave the parental protein and the product is the final ligand which is transported to the MHC-I-
containing compartment and is loaded onto MHC-I molecules. 
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 We considered all three possibilities to determine as accurately as possible the most 
likely antigenic substrates of transport through membranes in the absence of TAP.  
 In the first hypothesis, the protein itself can be transported through membranes in the 
absence of TAP. That would require that the proteins that harbor TAP-independent antigens 
share a common pattern or characteristic that allows them to be transported in a TAP-
independent way. As mentioned in Introduction, the study of the characteristics of twelve 
VACV proteins that harbor twelve TAP-independent peptides show that there is not a 
common link among them that differentiates them from proteins that do not harbor TAP-
independent antigens. Also, the fact that there are two VACV proteins each of them 
harboring a TAP-independent antigen and a TAP-dependent antigen at least indicates that a 
common characteristic among proteins harboring TAP-ind peptides cannot be the general 
rule for all of them. The hypothesis that the proteins access the vesicular pathway and they 
are entirely cleaved there to generate antigenic peptides is probably wrong, as most of VACV 
MHC-I-restricted TAP-ind antigen presentation requires the action of proteasomes (Figure 
16BandFigure 17). 
 That leaves two possible transport substrates: the antigenic peptide itself or a longer 
precursor. Our results show that TAP-independent antigenic peptides are more hydrophobic 
than TAP-dependent, but this differential hydrophobicity is also maintained in longer 
precursors, more markedly and farther for N-terminally elongated precursors (Figure 31). 
Thus, TAP-independent VACV antigens are strongly dependent on proteasomal action and 
TAP-independent VACV peptides as well as N-terminally elongated TAP-independent 
precursors are more hydrophobic than their TAP-dependent counterparts. With these data 
we propose a model of TAP-independent antigen processing and transport (Figure 36) in 
which proteasomes, possibly together with other cytosolic proteases, would cleave proteins 
in the cytosol and generate the final C-terminus of the MHC-I ligand. Highly hydrophobic N-
terminally extended proteasomal products would then be transported through membranes in 
the absence of TAP. The N-terminal extension would then be removed in the vesicular 
pathway by aminopeptidases (like ERAAP) to generate the correct MHC-I ligand, that would 
bind MHC-I molecules and be transported to the plasma membrane (Figure 36). 
Participation of luminal carboxypeptidases such as ACE in the TAP-ind pathway cannot be 
excluded but our analysis suggests that they would play a minor role. In fact, other similar 
study shows the importance of both proteasomes and metalloaminopeptidases in the 
generation of a TAP-independent cellular antigen (Oliveira et al., 2014), which agrees with 
our data on viral antigens (Figure 24A). 
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Figure 36. Model of TAP-independent antigen 
processing and transport. 
Our final model of TAP-independent viral antigen 
processing involves endo- and carboxypeptidase action in 
the cytosol by proteasomes and endo- and aminopeptidase 
action by and other proteases. Higher hydrophobicity of 
peptides would lead to the recognition and transport to 
MHC-I-containing compartments of N-terminally-extended 
precursors or the ligands themselves. N-terminally-extended 
precursors would be trimmed by aminopeptidases to 
generate the final ligand. 
 
6.4. Relevance of studying TAP-independent antigen processing 
pathways for vaccination and immunotherapy. 
6.4.1. TAP-independent pathways in the prevention of viral infections. Possibilities and 
limitations. 
 CD8+ T lymphocytes need to find their specific antigen presented on MHC-I 
molecules on a cell surface to perform their cytolytic action. Most of the antigens need the 
transport to the ER by TAP to be properly processed and presented. However, we have 
demonstrated the unexpected prevalence of TAP-independent viral antigen presentation 
pathways (Lázaro S. et al, in preparation). But, are these TAP-independent antigen 
presentation pathways relevant for the immune system in order to clear a viral infection in 
vivo? 
 TAP-deficient patients, although they suffer from recurrent bacterial infections, can 
control viral infections as efficiently as healthy patients (Gadola et al., 2000). In harmony with 
that observation, our results show that TAP1-/- mice can clear a VACV WR infection as 
efficiently as C57BL/6 mice (Figure 25). Hence, the deficiency in TAP does not lead to a 
complete shutdown of the immune system against viral infections. In particular, CD8+ T 
lymphocytes can also control a VACV WR infection in mice that lack TAP when they are 
previously primed with a TAP-independent epitope in the absence of priming of any other 
immune mechanism (Figure 27). Although CD8+ T lymphocyte response is enhanced for the 
TAP-ind epitope J3R after BMDC/peptide vaccination and VACV challenge, this does not 
occur for the TAP-ind epitopes A19L and A25L in TAP-/-mice (Figure 28). It is known that 
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antigen can affect the immune response, and this correlation is not lineal, but reaches a 
plateau, different for each epitope (Wherry et al., 1999; Tscharke et al., 2015). It may be 
happening that for J3R the VACV dose we used was sufficient to trigger a detectable 
production of IFNγ, while it was insufficient for the epitopes A19L and A25L. 
 However, our results also show a defect in viral clearance by CD8+ T lymphocytes in 
ovaries (in contraposition with spleens) when mice lack TAP (Figure 26). This differential 
capability of viral clearance by CD8+ T lymphocytes in the absence of TAP in different organs 
shows limitations for vaccination in the absence of TAP that need to be solved in order to 
develop efficient vaccines in TAP-deficient pathologies (TAP-deficient patients, tumors 
silencing TAP and viruses blocking TAP).Since this defect cannot be explained by a lower 
expression of MHC-I in TAP1-/- ovaries than in C57BL/6 ovaries (Figure 29B) and the 
epitopes assayed in ovaries were protective in spleens, it seems that there is no general 
limitation from the TAP-deficient presenting cell, unless there are tissue-specific proteases in 
different organs that limit the presentation of certain TAP-ind epitopes. 
By producing reactive oxygen and nitrogen species, neutrophils work together with 
CD8+ T lymphocytes to clear VACV in mice (Hickman et al., 2013). Hence, we could explain 
this differential antiviral CD8+ T lymphocyte efficiency between organs by a less effective 
infiltration of neutrophils in ovaries than in the spleen, leaving the CD8+ T lymphocyte action 
much less effective in ovaries (with less neutrophils) than in the spleen (with more 
neutrophils). It is known that the level of neutrophil infiltration in ovaries depend on the 
estrous cycle stage (Sasaki et al., 2011), and the estrous cycle itself is driven by a light/dark 
cycle (Miller et al., 2004). Since in our experiments we did not take into account the estrous 
cycle stage, we cannot assure the level of neutrophil infiltration in the ovaries at the time of 
the infection. Experiments detecting the level of neutrophil infiltration in spleen and ovaries in 
TAP1-/- and C57BL/6 mice under a VACV infection would need to be done to address this 
issue. 
It is also known that more than one contact between a CTL and an MCMV-infected 
cells is needed for the correct elimination of the target infected cell, being 3 contacts 
sufficient to extremely raise the probability of this elimination (Halle et al., 2016) (Figure 37). 
Our results show that ovaries, independently of the presence or absence of TAP, harbor 105 
more viruses than spleens in similar days post-infection (Figure 29A). Uninfected TAP1-/-
mice have between 8-30 times less CD8+ T lymphocytes than C57BL/6 mice in spleen, blood 
and lymph nodes (van Kaer et al., 1992). The data of the VACV-infected mice included in our 
experiments reveal10 times less CD8+ T lymphocytes in TAP1-/-spleens compared to 
C57BL/6 spleens and 4 times less CD8+ T lymphocytes in TAP1-/-PEC than in C57BL/6 PEC. 
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Also, it has been proposed that CTL response is not only determined by the number of CTL 
precursors for a given epitope, but also for the number of CTL precursors above a minimal 
affinity/avidity threshold (Tscharke et al., 2015), an unknown data for us. Therefore, we can 
assume that in TAP1-/-mice the contacts between infected cells and CTL are less frequent, 
making it more difficult to clear enough infected cells. This would be especially difficult in 
highly infected ovaries, but not so critical in spleens, which contain fewer infected cells. 
Figure 37. Probability of target-cell death for 
infected cells contacted by 0–14 CTL. 
(Halle et al., 2016)Data from two-photon in vivo 
imaging shows the probability of death of an MCMV-
infected cell attending to imaging data (red) or the 
null hypothesis (every CTL contact is an 
independent event and previous contacts do not 
influence the target cell’s death probability; white). 
 
 
Another variable that might be interfering with these results is that the infection route 
determines the virus spread and therefore, the viral load in different organs. In addition, CD8-
mediated specific cell lysis is higher when the organ is closer to the infection site (Lin et al., 
2013). Thus, our model of systemic intraperitoneal infection might be shaping the lytic 
capacity of CD8+ T lymphocytes in ovaries and spleen. 
All these hypotheses are not contradictory and could be working at the same time in 
our infection model. We would be in a scenario in which the absence of TAP does not 
impede the presentation of immunogenic and protective MHC-I-presented epitopes nor affect 
the functionality of the CTL themselves. The limitations in the elimination of viral infections in 
the absence of TAP would consist in (1) tissue-specific proteases that participate in the 
processing if these TAP-ind epitopes, (2) the synergic action of CTL and neutrophils and the 
efficiency for the latter to infiltrate in some tissues and/or (3) the ratio of CTL/infected cell, 
establishing an upper threshold of infected cells that restricts CD8+ T lymphocytes from 
performing a proper viral clearance. 
6.4.2. Interference of viral proteins with TAP. 
 It is widely known that some pathogens express proteins that interfere with elements 
of the antigen presentation machinery, lowering the direct presentation of antigens by the 
infected cells and therefore, lowering the cellular immune response (reviewed in (Mayerhofer 
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and Tampe, 2015)). TAP is one of the targets of these pathogens in their evolutionary 
struggle to attenuate the host immune system. In Table 11 the pathogen molecules that 
block TAP function in the host discovered so far are summarized. Of note, there is one 
protein expressed by bacteria, suggesting an important role of TAP and MHC-I molecules in 
the response against bacteria. Five proteins out of seven are encoded by viruses from the 
Herpesviridae family. These viruses are very common in the human population. According to 
the World Health Organization, about two thirds of the population under 50 are infected with 
HSV-1 (Looker et al., 2015a), HCMV prevalence in between 40-70 % of the adults 
(Lamberson and Dock, 1992). This number rises to 90 % during the first two decades of life 
of individuals worldwide for EBV (Ng and Khoury, 2009). 
Organism Protein Mechanism of action References 
H
e
rp
e
s
v
ir
id
a
e
 
HSV-1 ICP47 Binds to peptide-binding 
region of human TAP. 
(Lacaille and 
Androlewicz, 
1998) 
HCMV US6 Binds from ER lumen to 
human TAP, changing to an 
ATP non-binding 
conformation. 
(Hewitt et al., 
2001) 
Varicelloviruses 
(BHV/EHV/PRV/VZV) 
UL49.5 Ubiquitination of TAP leading 
to degradation/inhibits ATP 
binding to TAP. 
(Koppers-Lalic et 
al., 2005) 
(Koppers-Lalic et 
al., 2008) 
(Koppers-Lalic et 
al., 2008) 
EBV BNLF2a Blocks ATP and peptide 
binding to TAP. 
(Croft et al., 
2009) 
Murine γ-herpesvirus-68 MK3 Ubiquitination of TAP leading 
to degradation. 
(Boname et al., 
2005) 
P
o
x
v
ir
id
a
e
 CPXV CPXV12 Inhibits peptide translocation 
by binding ATP site. 
(Alzhanova et al., 
2009) 
 
B
a
c
te
ri
a
 Pseudomonas 
aeruginosa 
Cif Ubiquitination of TAP leading 
to degradation. 
(Bomberger et 
al., 2014) 
 
Table 11. TAP inhibitory molecules expressed by pathogens. 
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Molecules expressed by pathogens that interfere with the function of TAP in the infected cell are 
summarized in this table. HSV-1: Herpes simplex virus 1; HCMV: Human cytomegalovirus; BHV: 
Bovine herpes virus; EHV: Equine herpes virus; PRV: Pseudorabies virus; EBV: Epstein-Barr virus; 
CPXV: Cowpox virus. 
6.4.3. TAP-independent pathways in cancer immunotherapy. 
 The first treatments of cancer started after World War II, when it was observed that 
alkylating agents killed growing cancer cells by damaging their DNA. The first cancer was 
cured in 1956 with the compound methotrexate, which is still commonly used in 
chemotherapy. Along with radiotherapy, chemotherapy has been widely used to treat many 
types of cancer. However, since both approaches are very aggressive for healthy cells and 
cause many side effects to the patients, other approaches have been developed to treat 
cancer. With the study of the biology of cancer, the blocking of oncogene products has 
developed into very efficient cancer therapies. In addition, identification of tumor-specific cell 
surface antigens has led to their targeting by antibodies and to effective cancer therapies. 
For instance, the antibody trastuzumab against the human epidermal growth factor receptor 
2 protein (HER2) was approved during the late 1990s to treat metastatic breast cancer 
(Goldenberg, 1999). The involvement and potential use of the natural immune response in 
the control of cancer cells was not noticed until the 2000s, when the first drugs that 
modulated the immune response were used. A good example is the anti-programmed cell 
death protein 1 (PD1) antibody nivolumab, which accomplished very promising results 
against solid tumors (Brahmer et al., 2010; Topalian et al., 2012) and nowadays is commonly 
used with very promising results. 
The treatment of cancer by modulating the immune response is possible because the 
action of CD8+ T lymphocytes is not limited to infected cells, but they can also recognize and 
kill malignant cells. As CD8+ T lymphocytes patrol through the organism, they may encounter 
tumor cells presenting tumoral antigens on their surface, leading to subsequent elimination of 
the malignant cell, provided the tumor tissue microenvironment is not suppressing or 
regulating their action. However, tumors that interfere with the antigen presentation 
machinery are common. Particularly, 75 % of them silence TAP expression (36 out of 
48)(Leone et al., 2013a). In these tumors, MHC-I surface expression is greatly diminished 
and CD8+T lymphocyte action is therefore limited. It is known that CD8+ T lymphocytes can 
recognize epitopes that are presented by different tumoral TAP-deficient cell lines (Wolpert et 
al., 1997; van Hall et al., 2006). Most of the work in mice has been done with the TAP-
deficient model RMA-S, which we show is less efficient in presenting antigens in the absence 
of TAP than primary cell cultures (Figure 15). This might be due to the fact that the 
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expression of the potential alternative transporter TAPL is diminished in RMA-S cells 
compared to their TAP-proficient counterpart RMA cells (Figure 14). Even so, many 
promising results have been achieved. Of note, the priming of WT mice with a peptide 
specific of TAP-deficient cells can prevent TAP-deficient tumor growth in these animals (van 
Hall et al., 2006). This group was the first in describing a class of antigens that are only 
presented in cells lacking TAP: “T-cell epitopes associated with impaired peptide processing” 
(TEIPP). This characteristic makes these epitopes very interesting for an immunotherapeutic 
approach, since trained CD8+T lymphocytes would only recognize and therefore eliminate 
cells lacking the transporter, leaving healthy cells untouched, unlike current treatments like 
chemotherapy or radiotherapy or oncogenic-specific inhibitors. This warrants safety in clinical 
trials and would solve the main problem of serious adverse effects of other treatments, 
making this new approach a potential substitution or complement of current tumor treatment. 
 Far from being an exception in some mouse model, CTL specific for antigens 
presented only by TAP-deficient cells have been found in healthy human donors (Lampen et 
al., 2010), widely opening a window for immunotherapy of TAP-silenced human cancers. 
 Currently, several approaches to fight cancer with immunotherapy are being 
performed. The first cancer immunotherapy approach that has achieved good results are the 
immune checkpoint inhibitors. These inhibitors are monoclonal antibodies that block the 
function of proteins like PD-1 or CTLA-4 that negatively regulate the proliferation and 
activation of CD8+ T lymphocytes. Thus, the blocking of these proteins unleashes the 
functionality of the CD8+ T lymphocytes. This approach is normally combined with other kind 
of cancer treatments like radiotherapy or chemotherapy, improving the recovery of up to 30 
% of the patients (Schumacher and Schreiber, 2015) 
 The underlying mechanism of this approach involves neoantigens. Neoantigens are 
antigens that arise in tumoral cells as a result of a mutation in a cellular protein. Therefore, 
CTL specific for one or more of these antigens would only clear tumoral cells, leaving healthy 
cells intact. The availability of different kinds of antigens that are exclusively expressed in 
tumoral cells provides us with another possibility to fight these malignant cells with our own 
immune system. However, there are limitations to this approach, since it is not known 
whether all tumors express neoantigens or TEIPPs, and the use of neoantigens in patients 
require the individual characterization of these antigens for every patient and the 
development of individual treatments, with the economic costs involved. In Table 12 it is 
summarized the main advantages and disadvantages of neoantigens and TEIPPs in the 
immunotherapy of cancer. 
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Antigens prefentially 
expressed by tumors 
Neoantigens TEIPPs 
Advantages 
Certain level of 
selectivity. Substitution 
of more aggressive 
therapies. 
Useful for the tumors with 
a high rate of mutation. 
TEIPPs can be common 
in the same kind of 
tumors in different 
patients. 
Disadvantages 
Non-complete 
selectivity. 
Distinct in every patient. 
Need to develop 
individual treatments. 
Limited to tumors that 
silence TAP. 
Table 12. Advantages and disadvantages of neoantigens and TEIPPs in cancer 
immunotherapy. 
 However, very few TEIPPs are described. The treatment of TAP-silenced tumors 
would be much eased by a database of TEIPPs for each human HLA. Therefore, the same 
kind of tumors in different patients could be treated just by characterizing the HLA expressed 
in each patient. Thus, the study and characterization of these epitopes could highly improve 
the treatment of some human cancers. Of note, TEIPPs presentation is restricted to cells that 
do not express TAP but do express the rest of molecules involved in the antigen presentation 
machinery, such as MHC-I molecules. The treatment of patients targeting TEIPPs would then 
be restricted to tumors with these characteristics.  
The high prevalence of viral infections and tumors that can block TAP function shows 
the importance of researching on TAP-independent antigen presentation in the seek for 
effective and safe vaccines. Characterizing TAP-independent viral antigens can lead us to 
find more easily and more rapidly proper candidates for vaccines to fight pathogens and 
cancers that can block TAP function. Also, finding common characteristics among TAP-
independent antigens that differentiate them from TAP-dependent antigens could help us 
predict TAP-independent epitopes in newly found pathogens that could block TAP as well as 
in tumors. 
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7. CONCLUSIONS. 
1. TAP-independent cross-presentation of OVA-coated beads does not require the SNARE 
protein Sec22b function, unlike TAP-dependent OVA-coated beads cross-presentation. 
2. Proteasomes participate to the same extent in the processing of VACV TAP-dependent 
and TAP-independent epitopes. 
3. Pro-protein convertases participate in the processing of at least one VACV epitope in both 
TAP-dependent and TAP-independent pathways. 
4. TAP1-/- mice clear VACV from spleens and ovaries in vivo as efficiently as C57BL/6 mice. 
5. Vaccination of TAP1-/-and C57BL/6 mice with VACV TAP-independent epitopes boosts 
CD8+ T lymphocyte-mediated anti-viral effect. 
6. VACV TAP-independent epitopes and N-terminally extended precursors are significantly 
more hydrophobic than their VACV TAP-dependent counterparts. 
7. CONCLUSIONES. 
1. La presentación cruzada independiente de TAP de bolitas recubiertas de OVA no requiere 
de la función de la proteína SNARE Sec22b, al contrario que su presentación cruzada TAP-
dependiente. 
2. Los proteasomas participan de la misma manera en el procesamiento de epítopos de 
VACV TAP-dependientes y TAP-independientes. 
3. Las pro-protein convertasas participan en el procesamiento de al menos un epítopo de 
VACV tanto en su vía TAP-dependiente como TAP-independiente. 
4. Los ratones TAP1-/- eliminan VACV de bazos y ovarios in vivo tan eficientemente como los 
ratones C57BL/6. 
5. La vacunación de ratones TAP1-/-y C57BL/6 con epítopos TAP-independientes de VACV 
mejora el efecto antiviral de los linfocitos T CD8+. 
6. Los epítopos TAP-independientes y sus precursores extendidos en amino son 
significativamente más hidrofóbicos que sus contrapartes TAP-dependientes. 
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